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A B S T R A C T
Myopia is a highly frequent ocular disorder worldwide and pathologic myopia is the 4th most common cause of
irreversible blindness in developed countries. Pathologic myopia is especially common in East Asian countries.
Ocular alterations associated with pathologic myopia, especially those involving the macular area—defined as
myopic maculopathy—are the leading causes of vision loss in patients with pathologic myopia.
High myopia is defined as the presence of a highly negative refractive error (>−6 to −8 diopters) in the
context of eye elongation (26–26.5mm). Although the terms high myopia and pathologic myopia are often used
interchangeably, they do not refer to the same eye disease. The two key factors driving the development of
pathologic myopia are: 1) elongation of the axial length and 2) posterior staphyloma.
The presence of posterior staphyloma, which is the most common finding in patients with pathologic myopia,
is the key differentiating factor between high and pathologic myopia. The occurrence of staphyloma will, in most
cases, eventually lead to other conditions such as atrophic, traction, or neovascular maculopathy. Posterior
staphyloma is for instance, responsible for the differences between a myopic macular hole (MH)—with and
without retinal detachment—and idiopathic MH. Posterior staphyloma typically induces retinal layer splitting,
leading to foveoschisis in myopic MH, an important differentiating factor between myopic and emmetropic MH.
Myopic maculopathy is a highly complex disease and current classification systems do not fully account for
the numerous changes that occur in the macula of these patients. Therefore, a more comprehensive classification
system is needed, for several important reasons. First, to more precisely define the disease stage to improve
follow-up by enabling clinicians to more accurately monitor changes over time, which is essential given the
progressive nature of this condition. Second, unification of the currently-available classification systems would
establish standardized classification criteria that could be used to compare the findings from international
multicentric studies. Finally, a more comprehensive classification system could help to improve our under-
standing of the genetic origins of this disease, which is clearly relevant given the interchangeable—but erro-
neous—use of the terms high and pathologic myopia in genetic research.
1. Introduction
Myopia is a common disorder estimated to affect approximately 1.6
billion people worldwide. This disorder is becoming increasingly pre-
valent and by the year 2020, it is estimated that up to 2.5 billion people
will be affected, with 27%–33% of these presenting high myopia.
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Prevalence rates for both myopia and high myopia are expected to
continue rising in the coming decades, which implies that ocular
complications and vision loss associated with this disorder will also
increase (Holden et al., 2016).
Globally, the prevalence of simple myopia is considered to be as
high as 81.6%–96.5% according to different series (Koh et al., 2016a,
2014, Lee et al., 2013, 2011). The prevalence of high myopia is difficult
to determine with certainty due to the lack of a standardized definition,
ranging from 1% to 4%, reaching its highest rates in East Asia with a
prevalence of 6.8–21.6%. High myopia is usually defined as a spherical
equivalent of > −6.0 diopters or an ocular axial length ≥26.0 or
26.5 mm (Ohno-Matsui, 2017; Silva, 2012; Wolf et al., 2014). None-
theless, there is some controversy surrounding these cut-off points, with
some authors contending that the spherical equivalent to define high
myopia should be > −8.0 diopters (Shimada et al., 2013).
The precise definition of pathologic myopia is also controversial.
Originally, pathologic myopia was described as the presence of struc-
tural changes causing vision loss in the context of high myopia (Morgan
et al., 2012; Tokoro, 1988). Although axial elongation is generally be-
lieved to play a key role in these degenerative changes (Moriyama et al.,
2011), axial elongation is not, by itself, the only marker of pathologic
myopia given that posterior staphyloma has been occasionally reported
in eyes without high myopia (Wang et al., 2016).
Changes to the shape of the globe induced by pathologic myopia are
responsible for the macular, peripheral, and optic disc alterations de-
scribed in these patients. These structural changes—particularly the
macular alterations—may, over time, cause severe vision loss in pa-
tients with severe myopia (Morgan et al., 2012; Ohno-Matsui et al.,
2016c). Indeed, pathologic myopia is one of the leading causes of
blindness worldwide, accounting for 5.8%–7.8% of cases of blindness in
Europe (Cedrone et al., 2006). In China, it is estimated that pathologic
myopia may be responsible for complete vision loss in up to 6.7 million
people, with a further 7.1 million presenting low visual acuity (Cheng
et al., 2013).
Myopic macular degeneration is one of the main causes of irrever-
sible blindness in certain regions of the world, becoming an important
problem particularly in East Asia (Iwase et al., 2006). In Japan, this
degenerative disease accounts for 12.2% of severe vision loss (Yamada
et al., 2010). The leading cause of blindness in East Asia are compli-
cations related to pathologic myopia (Chan et al., 2016; Foster and
Jiang, 2014; Morgan et al., 2012). In Spain, pathologic myopia is the
4th leading cause of legal blindness, only exceeded by age-related
macular degeneration, glaucoma, and diabetic retinopathy (Gomez-Ulla
and Ondategui-Parra, 2012). It is estimated that approximately 900,000
people in Spain (2%–3% of the population) have pathologic myopia. In
consistency with the rising prevalence rates worldwide, pathologic
myopia has also become more common in Spain in recent years
(Gomez-Ulla and Gil-Martinez, 2015).
2. Posterior staphyloma
2.1. Concept
The presence of a posterior staphyloma is the most characteristic
finding, and the main marker, of pathologic myopia (Ohno-Matsui
et al., 2016c). Spaide defined posterior staphyloma as “an outpouching
of the wall of the eye that has a radius of curvature that is less than the
surrounding curvature of the wall of the eye” (Spaide, 2013). This was
the first widely-accepted definition of posterior staphyloma; however,
Ohno-Matsui et al. observed that peripapillary and nasal staphylomas
do not always induce a drastic curvature compared to surrounding
tissues, but rather a nasal distortion of the eye shape (Ohno-Matsui
et al., 2012), leading those authors to add “a nasally-distorted type of
globe” to the definition of staphyloma. In a later study, that same group
(Ohno-Matsui et al., 2016c) suggested that posterior staphyloma should
not be considered a characteristic lesion of myopic maculopathy,
contradicting earlier studies (Avila et al., 1984; Chang et al., 2013;
Chen et al., 2012; Gao et al., 2011; Vongphanit et al., 2002a), but rather
the main cause of myopic maculopathy.
Nevertheless, while most ophthalmologists would agree that pos-
terior staphyloma is likely one of the main causes of myopic maculo-
pathy, it cannot be considered its only cause given that axial elongation
without posterior staphyloma can also lead to myopic maculopathy,
although this is much less common (Ohno-Matsui et al., 2016c). It is
likely that excessive axial elongation may trigger stress in the posterior
pole that may lead to the appearance of local or diffuse degeneration of
the sclera and/or retina and/or choroid, and that any of these degen-
erative changes can induce pathological changes in the other tissues.
Even though posterior staphyloma may not be the primary defect,
its appearance does determine more severe alterations and a higher
prevalence of myopic maculopathy. Myopic traction maculopathy
(Baba et al., 2003; Benhamou et al., 2002; Hirakata and Hida, 2006; Oie
et al., 2005; Rahimy et al., 2013; Wu et al., 2009) and diffuse chor-
ioretinal atrophy (Ohno-Matsui, 2014) are significantly more common,
while best corrected visual acuity (BCVA) has been reported to be lower
in eyes with staphyloma than in eyes that do not show it (Ohno-Matsui,
2014; Steidl and Pruett, 1997).
Increasing age and axial length are relevant risk factors related to
the appearance of pathologic alterations in highly myopic patients
(Chen et al., 2012; Shih et al., 2006; Verkicharla et al., 2015) as well as
in eyes with staphyloma progression (Gözüm et al., 1997), Even though
young highly myopic patients do not tend to show posterior staphy-
lomas (Kobayashi et al., 2005), they can be found in 13.2% of young
highly myopic patients aged 3–19 years old. Logically and in line with
these authors’ results, the prevalence of posterior staphyloma rises to
53.5% in patients aged 60–86 years old (Curtin, 1977).
Optical coherence tomography (OCT) is a non-invasive imaging tool
that has vastly improved our ability to study and detect changes at
different levels of the posterior pole. Longer wavelength
(1.050–1.060 nm), deep penetrance swept-source (SS)-OCT offers clear
visualization of the sclera and orbital fat tissue, thus facilitating mor-
phological analysis of the posterior pole in eyes with high myopia.
However, it is often difficult to obtain good quality images in patients
with high myopia due to the characteristic lengthening of the posterior
part of the globe.
Horizontal SS-OCT b-scans of the macula in highly myopic patients
reveal a progressively increasing concavity as the axial length increases
and different slopes depending on the size and location of the staphy-
loma. At first, the concavity is minimal (Fig 1a), but over time it in-
creases, eventually involving the optic disc (Fig 1b). In some cases, the
optic disc can be seen at the bottom of the concavity (Fig 1c). The
profile may be regular (Fig 1d, e) or, less commonly, presents a clear
irregularity (Fig 1f). In most cases, vertical b-scans produce regular,
concave-profile images (Fig 1g), with the exception of dome-shaped
macula (DSM) (Fig 1h).
It has been postulated that several different mechanisms—involving
the process of emmetropization and structural defects in collagen fi-
bres—can cause posterior staphyloma. In highly myopic eyes, posterior
staphyloma appears to be related to a defective scleral structure.
Grossniklaus and Green evaluated the histological characteristics of 308
highly myopic eyes (Grossniklaus and Green, 1992), finding that the
two most common histological findings were a myopic configuration of
the optic nerve (a tilted disk in almost 40% of the eyes) and staphyloma
(35% of eyes), which was primarily located in the posterior pole.
Scleral changes in highly myopic eyes involve diffuse of local
thinning, with thinned collagen bundles, greater interfibrillary separa-
tion, decreased collagen striations, and a lamellar structure similar to
that of corneal stroma, seemingly permitting sliding of the scleral la-
mellae (Curtin and Teng, 1985). Posterior staphyloma is characterized
by the presence of an abrupt margin. Compared to the normal retina,
the ectatic area has a relative pallor associated with an increased visi-
bility of choroidal vessels (Fig 2). The height of the staphyloma
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correlates with the extent of scleral thinning. Ohno-Matsui et al. de-
scribed the presence of multiple conus pits in highly myopic eyes
(Curtin, 1977; Ohno-Matsui, 2016). Those authors also reported a
condition resembling peripapillary scleral schisis in the neighbouring
areas. Posterior staphyloma is frequently associated with chorioretinal
atrophy. In fact, these two signs are the most common myopia-related
macular findings, occurring in around 20–23% of highly myopic eyes in
adults (Chang et al., 2013).
Fig. 1. Horizontal swept-source optical coherence tomography b-scans of the macula of highly myopic eyes. A progressively increasing concavity is observed as axial
length grows, growing from a small concavity (a) to larger concavity (b). In other cases, the optic disc is seen at the bottom of the concavity (c). The profile may be
regular (d, e) or, in some cases, clearly irregular (f). In most cases, vertical b-scans show regular, concave-profile images (g) with the exception of dome-shaped
macula (h).
Fig. 2. Vertical posterior staphyloma in a highly
myopic eye with marked RPE and chorioretinal
atrophy (a). 34-year-old highly myopic patient with
a posterior staphyloma, after scleral buckling surgery
(b). Magnetic resonance imaging of an aphakic
highly myopic patient after left eye retinal detach-
ment surgery, showing intraocular gas in the anterior
chamber and posterior staphyloma (c, d).
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2.2. Classification
Curtin classified posterior staphyloma into 10 types—five primary
and five compound forms—based on their funduscopic appearance (Fig
3). In his system, primary staphylomas are classified according to the
area they involve, as follows: posterior pole of the eye (Type I), macular
area (Type II), peripapillary area (Type III), the area nasal to the disk
(Type IV) and the area below the disk (Type V). Compound staphy-
lomas are primarily type I staphylomas combined with other forms
(Types VI and VII) or that involve multiple steps across the wall of a
primary Type I staphyloma (Type VIII). By contrast, Types IX and X are
formed by a Type I staphyloma divided into compartments (Curtin,
1977).
Posterior pole staphyloma (Type I) is by far the most common type
of staphyloma. By contrast, the least common types are peripapillary
and inferior staphylomas, both of which are rare. Staphylomas tend to
expand and deepen with age, eventually becoming symmetric. Legal
blindness is more prevalent in eyes with staphyloma types VII, VI and
III and blindness is most commonly associated with diffuse chorior-
etinal atrophy affecting the peripapillary area. In Curtin’s series of 403
eyes with staphyloma, the mean overall prevalence of staphyloma-re-
lated blindness was 34.5%, ranging from 13% to 53.5%, respectively, in
the youngest and oldest age groups.
Ohno-Matsui expanded on Curtin’s classical classification by adding
nasal and peripapillary staphylomas with nasal distortion (Ohno-
Matsui, 2014). Those authors found that, in two-thirds of cases, both
eyes in highly myopic patients have a similar shape, and the part of the
fundus that most protrudes is usually located along or slightly below the
central sagittal axis. In that study, almost half of the eyes had multiple
protrusions and thus were more likely to present myopic chorioretinal
atrophy.
Recently-developed imaging technologies have improved the
quantification and classification of staphylomas. Ikuno et al. used
spectral-domain (SD)-OCT to measure posterior staphylomas in highly
myopic eyes, finding that the size of the staphyloma closely correlated
with refractive errors, choroidal thickness, and axial length (Ikuno
et al., 2009). Other authors have used SS-OCT to determine the contour
of the outer surface of the eyes and thus to establish the relationship
between the shape of this area and myopic chorioretinal lesions.
Recently, a new system was proposed to classify the curvatures of
the inner sclera according to data obtained through SS-OCT and
magnetic resonance imaging (MRI) (Ohno-Matsui, 2016). The authors
of that study suggested that the inner scleral surface in highly myopic
eyes has four different curvature patterns, as follows: 1) Curvatures that
slope toward the optic nerve, in which the scleral curvature is almost
flat, with the optic nerve located in the lower part of the fundus and the
fovea on the slope towards the optic disc. This pattern can be observed
mostly on horizontal OCT scans; 2) Symmetrical curvatures centred on
the fovea in which the sclera appears at the bottom of the fundus,
protruding towards the orbital apex. Both of these first two patterns are
similar to those found in emmetropic eyes; 3) Asymmetrical curvatures
in which the sclera protrudes strongly towards the orbital apex while
the most inferior part of the fundus is away from the fovea. All of the
eyes in that study that were classified as asymmetrical curvatures pre-
sented a staphyloma; and 4) Irregular curvatures in which the scleral
curve is irregular. Our group previously described the use of SS-OCT to
characterize highly myopic eyes; in that study, we observed patterns
similar to those described above (Ruiz-Moreno and Ruiz-Medrano,
2015).
Due to the extreme thinness of the choroid in highly myopic eyes,
the curvature of both the retina and Bruch’s membrane closely follow
that of the sclera. In emmetropic eyes, however, this pattern is not
followed because the choroid is much thicker; moreover, although there
are two different scleral curvature patterns (types 1 and 2, described
above, i.e., either sloping towards the optic disk [type 1] or symme-
trical [type 2]), the curvature of the retinal pigment epithelium (RPE) is
not necessarily identical to the curvature of the sclera. In the series by
Ohno-Matsui et al. (Ohno-Matsui, 2014), the staphyloma was present
along the anteroposterior axis in almost 80% of eyes and in the inferior
sclera in the remaining 20%, a finding that suggests that the inferior
sclera was thinner and more likely to present staphyloma. Patients with
irregular curvatures were older, more myopic, and had thinner central
thickness compared to younger patients. Those authors hypothesized
that the greater weakness in this area might be attributable to its lo-
cation at the closure of the embryonic ocular fissure.
The mean scleral thickness (228 μm) in highly myopic eyes de-
scribed by Ohno-Matsui and colleagues was similar to that reported by
Curtin and Teng (233 μm) and by Imamura et al. (281 μm) (Curtin and
Teng, 1985; Imamura et al., 2011; Ohno-Matsui et al., 2012). The
prevalence of posterior staphyloma in those studies was highest (100%
of the cases in both studies) in eyes with asymmetrical, irregular
chorioretinal and patchy atrophy. Myopic choroidal neovascularization
Fig. 3. Curtin classification of staphylomas. Primary staphylomas involve the posterior pole of the eye (Type I – Type V). Types VI and VII are compound staphylomas
combining Type I with other forms. Type VIII is formed by a Type I with multiple steps across its walls. Type IX and X are formed by a Type I staphyloma divided into
compartments. From (Curtin 1977).
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(mCNV) was more prevalent in eyes with irregular staphyloma. The
presence of myopic traction maculopathy (MTM) was more frequent
among eyes with irregular, asymmetric staphylomas. Ohno-Matsui et al.
found that irregular curvatures were more common among elderly
patients and in eyes with longer axial lengths and that those eyes were
more likely to present lesions characteristic of high myopia (Ohno-
Matsui et al., 2012). Miyake et al. used colour maps created through
OCT, finding that eyes with chorioretinal atrophy show a steep, curved
shape with an undulated surface in the posterior pole (Miyake et al.,
2014b).
Numerous authors have assessed the role of staphylomas in the
development of chorioretinal atrophy. A clinical quantification of pos-
terior staphyloma showed that a shallower staphyloma depth was as-
sociated with worse BCVA and a higher prevalence of mCNVs; by
contrast, larger staphylomas were associated with a higher prevalence
of conus formation, RPE defects, lacquer cracks, and chorioretinal
atrophy (Steidl and Pruett, 1997). Studies using ultrasound and MRI to
obtain three-dimensional (3D) images of myopic eyes have detected an
association between chorioretinal atrophy and the presence of two or
more protruding areas in the back of the eye (Moriyama et al., 2011).
Miyake et al. (Miyake et al., 2014a) used OCT imaging to response to
anti- vascular endothelial growth factor (VEGF) treatment for mCNV,
finding an association between chorioretinal atrophy and larger pos-
terior pole curvatures and undulations. In that same study, chorior-
etinal atrophy in eyes with mCNV was associated with lower to mod-
erate curvature; no association between retinal detachment and
retinoschisis was found. Enhanced-depth imaging OCT (EDI-OCT) has
also been used to evaluate the sclera and to determine the mean sub-
macular scleral thickness. Hyashi et al. and Imamura et al. used EDI-
OCT to measure subfoveal scleral thickness in highly myopic eyes,
finding a mean, respectively, of 284 μm and 291 μm (range,
132–434 μm) (Hayashi et al., 2013; Imamura et al., 2011).
Several groups have used high-resolution MRI with 3D volume
rendering to analyse the topography of the myopic fundus (Moriyama
et al., 2011; Ohno-Matsui et al., 2012). Based on the findings from those
studies, the authors classified highly myopic eyes according to their
shape into different types based on the degree of symmetry between the
temporal and nasal halves of the posterior eye segment. Laterally-
symmetric eyes were subdivided into barrel and cylinder types. Eyes
showing asymmetry in the temporal and nasal halves were further
subdivided into nasal and temporal distortion. Nearly 80% of patients
presented a symmetric shape in both eyes.
Posterior staphyloma deepens and changes its shape with age. Type
I or II staphylomas may evolve into a type IX staphyloma due to the
development of a ridge-like protrusion temporal to the optic disk re-
sulting in stretching of the peripapillary sclera (Hsiang et al., 2008).
Ohno-Matsui and colleagues (Ohno-Matsui, 2014) evaluated the
role of staphyloma in the development of myopic maculopathy. In that
study, the authors concluded that diffuse chorioretinal atrophy and
mCNV were more common in staphylomatous eyes than in eyes without
staphyloma. They also found that MTM was more common in highly
myopic eyes without staphyloma or in eyes with irregular, asymmetric
staphyloma.
Fernandez-Vega et al. found that the following conditions were all
more common in staphylomatous vs. non-staphylomatous eyes: RPE
alterations, neurosensory retinal detachment, retinal cysts, re-
tinoschisis, edge-related mCNV, polypoidal vasculopathy, and optic
disk and visual field damage. This location of mCNV is less common
than mCNV in the staphyloma fundus. Also, the protrusion appears to
have a greater height in eyes without mCNV. Eyes with relative scleral
thickening may have a lower risk of neovascular complications
(Ellabban et al., 2014; Ohsugi et al., 2013).The aforementioned con-
ditions are more common in inferior and inferonasal staphylomas
(Curtin’s Type V), although they may arise in other types of staphy-
loma; moreover, any convexity or edge protruding towards the vitreous
cavity might be associated with these conditions (Coco et al., 2012).
Hayashi et al. found that subfoveal scleral thickness was associated with
staphyloma height but not with the extent of chorioretinal atrophy
(Hayashi et al., 2013). Those findings are somewhat controversial
considering that other authors have found scleral thickness to be as-
sociated with lacquer cracks, mCNV, chorioretinal atrophy, and myopic
conus (Steidl and Pruett, 1997).
Fig. 4. Progressive retinal, choroidal and RPE
thinning and atrophy starting from a lacquer
crack (a) permitting visualization of choroidal
vessels and sclera (b). Spectral domain OCT
shows retinochoroidal thinning with myopic
choroidal neovascularization (c) and dome-
shaped macula (d), with concave sclera and lo-
calized submacular serous retinal detachment.
J. Ruiz-Medrano et al. Progress in Retinal and Eye Research 69 (2019) 80–115
84
3. Myopic maculopathy
Among the many clinical features of high myopia, probably the
most characteristic are those conditions that affect the posterior part of
the eye due to axial length elongation, stretching of the posterior eye
wall, and staphyloma. These changes may also threaten vision since
they often lead to irreversible retinal photoreceptor damage and central
visual loss. Scleral ectasia involving the posterior pole of the eye is
relatively common, usually leading to poor visual prognosis in adults.
Most of the complications related to myopic maculopathy may lead to
irreversible macular photoreceptor damage and central visual loss.
The following are considered the most characteristic findings of
myopic maculopathy (Fig 4):
• Retinal, choroidal, and scleral thinning (Ikuno et al., 2013; Ohno-
Matsui et al., 2018), which often present as variably-shaped pos-
terior staphylomas (Curtin and Karlin, 1971).
• Chorioretinal atrophy, which may appear in different patterns, such
as tessellated fundus, diffuse atrophy, patchy atrophy, and lacquer
cracks.
• Choroidal neovascularization (Ruiz-Moreno et al., 2009a, 2010,
2011, 2013b, 2015; Silva et al., 2010).
• Maculopathy associated with tractional changes in myopic eyes has
varying consequences, including myopic macular hole (MH), and
myopic foveoschisis, among others.
• Dome-shaped macula, characterized by the concave shape of the
sclera and often associated with serous, non-progressive retinal de-
tachment (Gaucher et al., 2008).
• Macular Bruch membrane holes, as a distinct form of chorioretinal
atrophy (CRA) characterized by the absence of the choriocapillaris,
Bruch’s membrane, RPE, and photoreceptors. Bruch’s membrane
holes can be a hallmark of patchy atrophy and can be associated to
lacquer cracks, staphyloma or diffuse atrophy (Ohno-Matsui et al.,
2016a).
In 1970, Curtin and Karlin were the first to propose a definition for
myopic maculopathy, which included the presence of all of the fol-
lowing: chorioretinal atrophy; central pigment spots; lacquer cracks;
posterior staphyloma; and optic disc changes (Curtin and Karlin, 1971).
Tokoro would later classify myopic maculopathy into four categories:
1) tessellated fundus, 2) diffuse chorioretinal atrophy, 3) patchy chor-
ioretinal atrophy, and 4) macular haemorrhage (Tokoro, 1998). Avila
proposed a new classification system in 1984 (Avila et al., 1984). De-
spite the numerous proposed classification systems, most published
studies on pathologic myopia have not used any of these (Avisar et al.,
2006; Buch et al., 2004; Cedrone et al., 2003; Cotter et al., 2006; Iwase
et al., 2006; Klaver et al., 1998).
Liu et al. defined “degenerative myopia” as follows: ≥ 6 negative
diopters in the presence of atrophic changes and stretching of the ma-
cula (Liu et al., 2010). Asakuna defined myopic maculopathy as the
presence of ≥ one of the following: diffuse chorioretinal atrophy at the
posterior pole, patchy chorioretinal atrophy, lacquer cracks, or macular
atrophy (Asakuma et al., 2012). The definition of this entity proposed
by Vongphanit et al. was as follows: the presence of staphyloma, lac-
quer cracks, Fuch’s spot, and myopic chorioretinal thinning or atrophy
(Vongphanit et al., 2002b). Given these heterogenous definitions and
terminology, an international group of experts in high myopia met in
order to develop a simplified, systematic classification based on a meta-
analysis of pathologic myopia (META-PM) (Ohno-Matsui et al., 2015).
This group classified myopic maculopathy into five different categories
based on atrophic changes, as follows: no myopic retinal lesions (ca-
tegory 0), tessellated fundus only (category 1), diffuse chorioretinal
atrophy (category 2), patchy chorioretinal atrophy (category 3), and
macular atrophy (category 4). Up to three “plus” signs could be added
to any of these categories to indicate the presence of lacquer cracks,
mCNV, and Fuch’s spot. The developers of that classification system
emphasized their hope that future epidemiological studies and clinical
trials would adopt this classification system in order to standardize
findings. That system was an important step forward, as it greatly
simplified the identification of atrophic changes into defined categories,
while also allowing for a neovascular component to be added. However,
many patients with macular alterations due to high myopia are not
sufficiently represented by that atrophy-centred classification system.
Patients with vitreomacular interface alterations caused by longer
axial length, as occurs in patients with myopic foveoschisis, should also
be included in pathologic myopia classification systems. At present,
however, the classification proposed by Ohno-Matsui et al. does not
include macular conditions of tractional origin or neovascular macu-
lopathy, which, even if they are present, are only considered as an extra
factor in other categories. Given these drawbacks, one of the aims of the
present review is to propose a new, more comprehensive classification
system, which is described in detail at the end of this document.
Given that some eyes present axial elongation in the context of high
myopia but show no alterations in the curvature of the posterior
pole—that is, axial myopia without staphyloma - it is clear that axial
elongation alone is insufficient for a diagnosis of posterior staphyloma.
In fact, posterior staphyloma has been described in eyes without high
myopia (Wang et al., 2016). Nevertheless, it must be acknowledged that
the vast majority of patients with posterior staphyloma present axial
elongation. The development of a posterior staphyloma induces a large
increase in axial length, while the surface of the posterior pole—-
including the macular area and the optic disc—widens substantially, up
to twice the size of regular eyes (Ohno-Matsui et al., 2016c). Another
working hypothesis is that excessive axial elongation triggers stresses in
the posterior pole of the eye, which can lead—almost stochastically—
to degeneration in the retina and/or choroid, rupture of Bruch’s
membrane, and staphyloma. In the presence of any of these alterna-
tions, other pathological changes are accelerated due to an increase in
stresses and strains.
One of the aims of the present review is to provide a straightforward
definition of “myopic maculopathy”. The proposed definition is as fol-
lows: macular alterations induced by high myopia, in which an ex-
cessive axial length and/or posterior staphyloma is the main common
factor but not the only factor (as we discuss later in this paper). These
macular alterations include not only atrophic changes, which are the
basis of the majority of current classifications, but also neovascular
alterations, traction-induced changes to the macula, and specific mod-
ifications of the posterior pole profile that may cause myopia-related
conditions, such as DSM. For these reasons, myopic maculopathy can be
classified into one of three categories: 1) atrophic myopic maculopathy,
2) neovascular myopic maculopathy, and 3) tractional myopic macu-
lopathy. However, none of these should exclude the others, as different
types of myopic maculopathy may coexist in the same eye, as we have
observed in our clinical practice.
The main factor that is common to all three of these categories is the
presence of increased axial length, posterior staphyloma, or both,
leading to a decrease in BCVA. One study found a linear correlation
between the degree of staphyloma and the presence of atrophy or lac-
quer cracks (Steidl and Pruett, 1997). Ohno-Matsui found that BCVA
was lower in eyes with staphyloma (regardless of type) compared to
eyes without any staphyloma (Ohno-Matsui, 2014). Diffuse chorior-
etinal atrophy and myopic traction maculopathy are significantly more
common in eyes with a wide staphyloma (Ohno-Matsui, 2014).
Paradoxically, a preserved choriocapillaris is theoretically required
for mCNV to develop, which is why mCNV seems more common in eyes
with less advanced staphylomas. However, Ishida et al. used SS-OCT to
evaluate 124 eyes from 112 patients with mCNV, finding a possible
direct communication between short posterior ciliary arteries and CNV
through a defect in Bruch's membrane (Ishida et al., 2018); on the other
hand, OCT-based studies of staphylomas describe a high prevalence of
MTM (Baba et al., 2003; Benhamou et al., 2002; Forte et al., 2007;
Henaine-Berra et al., 2013; Hirakata and Hida, 2006; Oie et al., 2005;
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Panozzo and Mercanti, 2004; Rahimy et al., 2013; Takano and Kishi,
1999; Wu et al., 2009). Vitreoretinal interface alterations are more
common in larger staphylomas (Ripandelli et al., 2008).
Myopic MH is more common among eyes with posterior staphy-
loma. Oie et al. compared highly myopic eyes with full-thickness MH,
with and without retinal detachment, concluding that posterior sta-
phylomas are significantly more common in eyes with MH-related
retinal detachment (Oie et al., 2005).
Both Ohno-Matsui et al. and Verkicharla et al. (Ohno-Matsui, 2014;
Verkicharla et al., 2015) suggest that pathologic myopia should be
defined as category 2 myopic maculopathy, with the presence of plus
signs or posterior staphyloma. However, we disagree with those au-
thors. In our opinion pathologic myopia should be defined as the pre-
sence of axial elongation or a posterior staphyloma that induces myopic
maculopathy. However, it is crucial to keep in mind the progressive
nature of pathologic myopia. In this regard, newer, more complete
classification systems are needed to include and better describe all of
these options. Moreover, the availability of a more comprehensive
system would facilitate follow-up of these patients.
4. Atrophic myopic maculopathy
Atrophic myopic maculopathy (AMM) could be considered the
myopic equivalent of atrophic AMD, either as the primary consequence
of myopic choroidopathy or as an outcome of neovascularization. AMM
is associated with a progressive decrease in BCVA.
Chorioretinal degeneration of the posterior pole is considered the
most common change in the fundus (Curtin, 1979). This condition has
been described as circumscribed areas of choroidal degeneration in-
itially involving the crescent and consisting of focal patches of tissue
deprived from the RPE and choriocapillaris, with pigment clumping
inside or at the edge of the lesion. These areas subsequently become
confluent, forming large geographic areas of atrophy that merge with
an enlarged peripapillary degenerative zone (Fig 5).
Although the pathogenesis of AMM is not well-understood, it is
believed to be associated with the staphyloma, which may cause local
changes to the choroid and retina that progressively damage the
neighbouring tissues; in addition, excessive axial elongation is asso-
ciated with stretching of the ocular coats, as evidenced by retinal vessel
straightening and chorioretinal thinning (Blach et al., 1965; Curtin,
1988, 1977; Curtin and Karlin, 1971). It is uncertain whether these
changes are part of a genetically-predetermined abiotrophic process
that is independent from scleral thinning, or whether these alterations
are caused by biomechanical changes induced by scleral expansion with
normal intraocular pressure, which is the more widely-accepted me-
chanism (Mcmonnies, 2016). These changes are probably induced by a
structural weakness that reduces the scleral mechanical resistance to
normal intraocular pressure or by the action of extraocular muscles. It
has also been suggested that the axis of astigmatism may play a role in
early myopic chorioretinal degenerative changes (Ahmad et al., 2010).
Light microscopy shows the effects of scleral elongation on the
posterior pole; these effects include scleral distension and thinning with
choroidal attenuation and loss, RPE pigment loss, and loss of the outer
retinal layers (Grossniklaus and Green, 1992). These degenerative
changes first affect the external retinal layers, only later affecting the
inner layers. These alterations are more evident in eyes with DSM, in
which Bruch’s membrane is often defective, and this defect may be
associated with the loss of the RPE as well as the outer and central
retinal layers and choriocapillaris (Fang et al., 2017). In this process,
the choroid degenerates and atrophies, larger choroidal vessels and
melanocytes disappear, and the choriocapillaris becomes thinner
(Grossniklaus and Green, 1992; Okabe et al., 1979). RPE cells become
enlarged and eventually degenerate and disappear and are replaced by
Müller cells. Bruch’s membrane becomes thinner, divided, and frag-
mented and the neurosensory retina becomes thinner.
As in AMD, aging affects the RPE and thus damage to the RPE is
more severe among elderly highly myopic patients. The RPE becomes
attenuated with pigment deposits. The spatial distribution of lipofuscin
generally matches that of rods and reflects the pattern of age-related
loss of rod photoreceptors. Lipofuscin fluorescence increases linearly
until the 8th decade and then declines; in such cases, the decrease in
autofluorescence may indicate removal of atrophic RPE cells (Delori
Fig. 5. Progressive enlargement of the area of chorioretinal atrophy surrounding the optic disk, which eventually involves the fovea.
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et al., 2001). Multifocal electroretinography reveals early functional
changes in the outer retina, which may precede chorioretinal atrophy
(Ishikawa et al., 1990).
Anteroposterior elongation induces progressive thinning and
stretching of the ocular layers, with retinal vessel rectification, retinal
and choroidal thinning, and the development of a tractional crescent.
Stretching of ocular tissues induces changes in choroidal haemody-
namics, causing loss of choroidal stroma and vessel obliteration, leading
to choroidal thinning (Stafford, 1982). Choroidal thinning, which has
been observed on EDI-OCT, is typically associated with age and the
degree of myopia (Fujiwara et al., 2009). Focal areas of atrophy may be
present; these areas typically appear as rounded or irregular forms and
they can be small or large, isolated or multiple; these foci tend to grow
and merge over time. Choroidal and RPE thinning facilitates visuali-
zation of larger choroidal vessels.
Even though atrophic changes are not always directly related to
ocular elongation, they often occur when elongation is present.
Occlusion of the large and small choroidal vessels leads to the devel-
opment of fibrotic tissue (Okabe et al., 1982) and photoreceptor loss
(due to reduced oxygenation), which reduces retinal thickness, thus
leading to central vision loss.
The choroidal volume on EDI-OCT is smaller in highly myopic eyes
than in emmetropic eyes, even without AMM (Barteselli et al., 2014).
To satisfy the metabolic demands of the normal retina, blood flow in the
choroid is high; however, a thinned choroid may be unable to provide
the required amount of oxygen and nutrients, which in turns negatively
affects retinal function. Some reports suggest that choroidal thinning
may predict the formation of lacquer cracks. AMM progression is pre-
ceded by choroidal thinning, which can be seen one both EDI-OCT and
SS-OCT, as reported by Zaben et al. (Zaben et al., 2015). AMM becomes
more severe over time (Ikuno et al., 2013) (Fig 6). In such cases, pa-
tients retain a relatively good BCVA until choriocapillaris atrophy in-
duces RPE atrophy (Gupta et al., 2016; Pang et al., 2015). As choroidal
thinning increases, the RPE becomes affected and blue autofluorescence
decreases (Fig 7). On SD-OCT, highly myopic eyes with AMM present
thinning of the retinal nerve fibre layer (Koh et al., 2016b). However,
the most striking findings are thinning of the choroid and chor-
iocapillaris followed by retinal destructuring.
Choroidal thinning is associated with age, axial length, sex, and
staphyloma. It is more intense in eyes with previous MTM or mCNV
(Barteselli et al., 2014). Studies have shown that extreme choroidal
thinning can be compatible with good BCVA as well as preserved
fundus autofluorescence (FAF), suggesting that choroidal thickness
alone is not a reliable indicator of visual function (Pang et al., 2015).
However, the complete disappearance of the choroid implies a definite
decline in BCVA.
On microperimetry, choroidal thinning is associated with diffuse
choroidal atrophy, lacquer cracks, and decreased macular sensitivity in
the external macular rings. Macular sensitivity decreases with age and
with the increasing severity of the myopia. Changes in the mean ma-
cular sensitivity correlate closely with choroidal thickness, age, sphe-
rical equivalent, and BCVA but not with retinal thickness (Zaben et al.,
2015).
Macular thinning causes dispersion of the luteal pigment and hin-
ders foveal localization. However, in the early stages of myopic elon-
gation, increased axial length has been associated with increased ma-
cular thickness (Lam et al., 2007), probably due to a mechanical effect
of vitreomacular traction, even in the absence of macular retinoschisis.
Systemic conditions may play a role in the development and en-
largement of macular atrophy. Chen et al. (Chen et al., 2012) identified
increased systemic blood pressure (BP) as a risk factor for developing
myopic maculopathy: an increase of 10mm Hg in systemic BP increases
the odds of developing maculopathy by a factor of 1.5 in highly myopic
patients after adjusting for confounding factors. Patients with more
severe forms of macular atrophy and mCNV have higher systemic BP
than patients with less severe macular changes. A similar association
has been found for exudative AMD (Klein et al., 2007). It has also been
reported that systemic BP influences choroidal thickness, with higher
BP associated with a thinner choroid, which may further compromise
choroidal thickness in hypertensive myopic patients, thereby affecting
choroidal circulation and aggravating myopic maculopathy (Usui et al.,
2012).
Aging has an impact on the anatomical and functional outcomes of
patients with myopic maculopathy. Shih et al. (Shih et al., 2006)
evaluated the effect of myopic maculopathy on BCVA, finding a sig-
nificant correlation between lower BCVA and age in myopic eyes. Those
authors also observed that aging was associated with more advanced
forms of AMM and worse BCVA, and with the development and coa-
lescence of atrophic areas, extension of lacquer cracks, increased areas
of atrophic choriocapillaris, and a higher likelihood of presenting
mCNV ingrowths from ruptured Bruch’s membrane (Ohno-Matsui and
Tokoro, 1996; Shih et al., 2006).
Lacquer cracks are ruptures in the RPE-Bruch's membrane-chor-
iocapillaris complex and are usually associated with posterior staphy-
loma. The presence of mCNV may indicate an anomalous response of a
wound-healing mechanism. These lesions appear as multiple yellowish-
white irregular lines, usually horizontally-oriented, and can be linear or
stellate, occasionally branching or crisscrossing. They are more
common in males and decrease with age. Fluorescein angiography (FA)
shows a window defect appearing as hyper-fluorescent tracks without
any leakage. On FAF, there is a hypoautofluorescent pattern.
Avila and colleagues were the first to propose a classification system
to describe the natural course of AMM based on FA and stereoscopic
fundus photographs. The proposed classification system consists of six
different grades ranging from M0 to M5, as follows: M0, normal-ap-
pearing posterior pole; M1, choroidal pallor and tessellation; M2,
choroidal pallor and tessellation with posterior pole staphyloma and
lacquer cracks; M3, Bruch’s membrane rupture with superficial chor-
ioretinal atrophy; M4, the same changes as M3 but with focal areas of
deep choroidal atrophy; and M5, the same as M4 plus large geographic
areas of deep choroidal atrophy (Avila et al., 1984). However, due to
the study design—a cross-sectional survey rather than a longitudinal
study—that classification system had some errors, such as including
staphyloma and lacquer cracks as part of the process of progression.
That classification system was later modified to include rounded
atrophic lesions and lesions surrounding lacquer cracks in stage M3
(Tokoro, 1998).
A few longitudinal studies have been performed to assess myopic
maculopathy progression caused by increasing atrophy (Vongphanit
et al., 2002b), which is associated with progressive vision decrease
(Shih et al., 2006). Of those studies, perhaps the most comprehensive
was performed by Hayashi et al., who observed that the early presence
of lacquer cracks and staphyloma subsequently affected the progression
of atrophy (Hayashi et al., 2010). Those authors retrospectively eval-
uated 429 highly myopic patients (spherical equivalent > −8.00
diopters or axial length ≥26.5 mm) who had more than 5 years follow-
up. Myopic maculopathy was classified according to a modified version
of Tokoro’s definition as follows: tessellated fundus, diffuse chorior-
etinal atrophy, patchy chorioretinal atrophy, and macular haemorrhage
(Tokoro, 1998). Patchy chorioretinal atrophy was further subdivided
into atrophy associated with lacquer cracks, atrophy associated with
posterior staphyloma, and circular lesions in areas with advanced dif-
fuse chorioretinal atrophy (Fig 8). The authors described a tentative
progression pattern for myopic maculopathy in which the first sign is a
tessellated fundus, which may progress to diffuse atrophy or lacquer
cracks or—less commonly—to mCNV. Lacquer cracks and patchy
atrophy are the most common predisposing factors for the development
of mCNV. Patchy atrophy represents a complete atrophy of the RPE-
choriocapillaris. Tissue damage at the edge of these lesions may induce
the development of mCNV (Ohno-Matsui et al., 2003). More recently,
Fang et al. reported on a large series of highly myopic eyes with a mean
follow-up of 18.7 ± 7.1 years (Fang et al., 2018). Progression to
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myopic maculopathy was detected in 74.3% of the eyes with pathologic
myopia and was more common in eyes with more severe forms of
atrophy, especially those that presented macular atrophy and patchy
atrophy at baseline. The risk of progression was higher among older
patients and those with parapapillary atrophy, longer initial axial
length, and axial elongation. Rates of progression were also higher
among elderly patients and women, mainly among those with patho-
logic myopia at baseline. The authors hypothesized that the holes in
Bruch’s membrane that appear in patchy atrophy might play a role in
this higher progression rate versus eyes with diffuse atrophy due to
choroidal thinning. This faster progression was observed even in the
absence of lacquer cracks or CNV and was attributed to the enlargement
of Bruch’s membrane defects following axial elongation. The authors
propose a progression scheme of myopic atrophy based on changes
related to choroidal thinning, from normal to tessellated fundus and
extension from peripapillary diffuse chorioretinal atrophy to macular
diffuse atrophy.
In the more severe forms of myopic atrophy, the atrophic changes
may be mostly related to the presence and enlargement of Bruch’s
membrane holes, such as the progression from lacquer cracks to patchy
atrophy and finally patchy-related macular atrophy, and the progres-
sion from myopic CNV towards CNV-related macular atrophy (Fang
et al., 2018) (Scheme 1 bottom). However, in that study the authors did
not evaluate the role of the staphyloma, an acknowledged limitation of
the study.
Diffuse atrophy can lead to circular areas of atrophy or to lacquer
cracks and to the formation of mCNV. Myopic CNV can progress to
macular atrophy in the surrounding areas (Fig 9). Lacquer cracks may
induce further localized atrophic areas, which grow from the border of
the cracks, or it may lead to the development of mCNV. Atrophic pat-
ches may coalesce to form larger atrophic areas leading to macular
atrophy. However, these atrophic changes do not progress in a uniform
manner. Increasing age and the presence of a staphyloma both promote
the development of atrophy.
In their series, Hayashi et al. observed that 40% of highly myopic
eyes—particularly eyes with posterior staphyloma—showed pro-
gressive chorioretinal atrophy. These findings suggest that posterior
staphyloma should not be considered a single stage in the classification
system, but rather a key component of the progression of atrophy.
Hayashi and colleagues further subdivided diffuse atrophy into lacquer
cracks and genuinely diffuse atrophy. Macular haemorrhages were
classified according to their association with mCNV, and areas of focal
atrophy were subdivided into three types: 1) atrophy originating from
lacquer cracks (more common in the perifoveal area), 2) atrophy that
develops within an area of diffuse atrophy, and 3) atrophy derived from
the staphyloma.
Hayashi et al. described the progression of myopic maculopathy
(Hayashi et al., 2010), as follows: tessellated fundi evolve into diffuse
atrophy with lacquer cracks, which is followed by progression and an
increasing area of patchy atrophy in eyes with lacquer cracks. Next,
there is enlargement of the diffuse atrophic areas followed by the
emergence of atrophic patches in eyes with diffuse atrophy. Finally, the
atrophic areas become enlarged and coalesce. These changes were less
evident in eyes with tessellated fundi. Those authors found that lacquer
cracks appeared at a relatively early stage of maculopathy and were
unrelated to other changes, such as diffuse atrophy or staphyloma,
Fig. 6. Macular choroidal thickness in an emmetropic eye (a) and in highly myopic eyes presenting a thin choroid in all four cases: (b) highly myopic eye with normal
retinal layers; (c) highly myopic patient showing myopic traction maculopathy, lamellar macular hole, and normal outer retinal layers; (d) highly myopic eye with
Fuch‘s spot and loss of outer retinal layers; (e) highly myopic eye with normal inner retinal layers and focal disruptions of outer layers.
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which theoretically, appear earlier than lacquer cracks.
Myopic CNV is more common in eyes with tessellated fundi, lacquer
cracks, and diffuse and patchy atrophy. Myopic CNV is followed by an
enlargement and coalescence of the atrophic areas, which further re-
duces visual function. Eyes with posterior staphylomas are more prone
to progressive tessellation towards diffuse and patchy atrophy.
Progression of these atrophic changes tends to occur more quickly in
more advanced stages beyond the tessellated fundus, and especially in
eyes that already present some degree of atrophy or mCNV.
Although intravitreal administration of anti- VEGF induces regres-
sion of the mCNV, chorioretinal atrophy still can appear around the
regressed mCNV. Moreover, this atrophic area may become enlarged,
thus reducing BCVA. Uemoto et al. (Uemoto et al., 2012) identified
three main factors associated with enlargement of the atrophic area
after intravitreal injection: 1) size of the mCNV at baseline; 2) number
of injections required to inactivate the lesion; and 3) duration of follow-
up. Those authors also observed that the extent of the decrease in
mCNV after treatment and the presence of subretinal blood might play a
role in determining the final outcome. Finally, the rate at which the
mCNV shrinks has been associated with the development of chorior-
etinal atrophy, which might be related to RPE damage induced by
centripetal contraction of the RPE surrounding the mCNV (Hayashi
et al., 2009; Uemoto et al., 2012).
Based on our clinical experience, several other factors may play a
role in this process: age; the time elapsed between mCNV development
and treatment; and the type of treatment used—photodynamic therapy
(PDT) induces more atrophy than intravitreal anti-VEGF drugs
(Montero and Ruiz-Moreno, 2003; Ruiz-Moreno et al., 2008, 2009a,
2010, 2011, 2013b, 2015; Silva et al., 2010).
The most common patterns of progression are from tessellated
atrophy to diffuse atrophy with lacquer cracks, followed by growth of
the atrophic areas surrounding the lacquer cracks and the diffuse
atrophy into atrophic patches and then by atrophy in the mCNV after
neovascularization, followed by coalescence of the atrophic areas.
Diffuse atrophy may evolve into atrophic patches or lacquer cracks with
or without mCNV, and lacquer cracks may lead to focal atrophy or
mCNV. Atrophic areas can merge to form geographic areas of atrophy
while mCNV may evolve into areas of diffuse atrophy. Age, axial length,
and staphyloma all seem to play a role in the progression of myopic
maculopathy (Hayashi et al., 2010) (Scheme 1).
Due to the wide clinical variation, the evaluation and classification
of highly myopic eyes is challenging. Yoshihara et al. developed a
classification system to quantify tessellation based on three tessellated
fundus indices. That system demonstrated good repeatability with re-
gard to the subjective and objective classification of the degree of tes-
sellation. In that system the mean red, green, and blue intensity are
Fig. 7. Fundus photography (a), swept-source optical coherence tomography (b) and blue autofluorescence (c) in a highly myopic patient. Loss of the choriocapillaris
is associated with decreased blue autofluorescecnce and disappearance of the RPE and outer nuclear layer.
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assessed in the area located between the fovea and the optic disk
(Yoshihara et al., 2014). More recently Ohno-Matsui et al. proposed a
new classification and grading system for myopic atrophy (Ohno-
Matsui et al., 2015). Those authors found that early atrophic chan-
ges—that is, tessellated and diffuse atrophy—were more common
among younger patients and those with milder myopia and shorter
axial lengths. However, Hayashi et al. found that, compared to diffuse
atrophy, patchy atrophy was associated with longer axial lengths, lac-
quer cracks, and mCNV (Hayashi et al., 2010).
Patients with patchy atrophy have a worse visual prognosis than
those with lacquer cracks, especially when the atrophic areas merge.
Aging further aggravates this atrophy by inducing enlargement and
coalescence of lacquer cracks, thus increasing the atrophic areas and
the risk of neovascularization. Perimetric defects are common in highly
myopic eyes. Myopic fundus lesions can explain some defects. Ohno-
Matsui et al. observed a decrease of nearly 15% in the outermost ma-
cular isopter in highly myopic eyes (Ohno-Matsui et al., 2011).
Electrophysiological findings usually show substantial alterations.
Electroretinogram (ERG) studies usually show that a and b waves are
equally affected, with deep a waves and reduced b waves. Dark adap-
tation is affected in eyes with more extensive atrophic changes (Blach
et al., 1966). The ERG wave amplitude pattern is inversely related to
axial length (Hidajat et al., 2003). Electrooculogram values are usually
low, but not necessarily below the lower limit of normal values. How-
ever, the extent of this reduction seems to be related to the degree of
chorioretinal atrophy (Blach et al., 1966).
Fluorescein angiography shows very low contrast in highly myopic
eyes due to the low choroidal blood flow and the decreased light ab-
sorption caused by choroidal and RPE thinning, which leads to an in-
creased reflection of light in the sclera. FAF studies show four well-
defined patterns: 1) an area of reduced FAF around lacquer cracks and
mCNV surrounded by an area of augmented FAF; 2) well-defined small
or multi-lobular areas with reduced FAF within an area of increased
FAF; 3) larger, well-defined lobular or multilobular areas of reduced
FAF within an area of increased FAF; and 4) wide areas of reduced FAF
in the regions of chorioretinal atrophy (Parodi et al., 2015; Sawa et al.,
2008). These areas of decreased FAF are associated with decreased
vision and emerge relatively late in the process despite the progressive
thinning of the choriocapillaris.
4.1. Management
At present, the available options to manage myopic chorioretinal
atrophy are limited, especially the most advanced forms of this condi-
tion. However, since patients maintain peripheral vision, low vision
aids—such as high-addition monofocal, bifocal, or trifocal lenses, and
hand-held or self-standing magnification systems—may be useful in
some cases. However, published data on the value of such aids is lim-
ited (Bray et al., 2017; Kollbaum et al., 2013; Vincent, 2017).
Early and aggressive management of myopic mCNV by intravitreal
anti-VEGF therapies may help to reduce the progression of atrophic
areas surrounding lacquer cracks and mCNV. An alternate approach
might be to limit the extent and progression of the posterior staphy-
loma, which reportedly plays a role in the progression of macular
atrophy (Steidl and Pruett, 1997). Some authors (Mateo et al., 2012)
have attempted to encircle the sclera behind the macula—as is done in
macular buckling to manage myopic foveoschisis with both hard sili-
cone implant and macular plombe—successfully reducing retinal
thickness with this technique. However, a drawback of this approach is
localized areas of RPE atrophy, which was the most common compli-
cation observed by Mateo and colleagues.
Presently there are no pharmacological treatments for chorioretinal
atrophy. However, human RPE transplantation may be useful to treat
degenerative retinal conditions. Transplantation of RPE sheets and
suspensions of individual RPE cells have been used to treat AMD and
this approach could also be used for myopic chorioretinal atrophy. We
recently searched www.clinicaltrials.gov (access date, May 29, 2018),
finding 62 entries for dry AMD, 278 for wet AMD, 23 for myopic CNV
and only 10 (3 of which were for stem cell therapy) for myopic macular
degeneration. One of the phase 1–2 trials (NCT02122159) identified by
this search involved subretinal injection of fully-differentiated human
RPE cells derived from embryonic stem cells (MA09-hRPE) in patients
with myopic macular degeneration. However, that trial had been
withdrawn from the database (as of May 29, 2018) for unknown rea-
sons. Two other trials (NCT01920867 and NCT03011541) are currently
underway. Those studies—which use a combination of retrobulbar,
Fig. 8. Chorioretinal atrophy progression patterns associated with diffuse chorioretinal atrophy (a,b), border of the staphyloma (c,d) and lacquer cracks (e,f)
according to Tokoro’s classification (Tokoro 1998).
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Scheme 1. Top: Progression patterns towards chorioretinal atrophy from a range of different initial lesions combined with the development of mCNV. Modified from
(Hayashi et al.2010). Bottom: Progression patterns related to changes in choroidal thinning and Bruch’s membrane holes. Modified from (Fang et al. 2018).
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subtenon, intravitreal, intraocular, subretinal, and intravenous injec-
tions of autologous bone marrow-derived stem cells—are currently re-
cruiting patients with various retinal or optic nerve conditions such as
macular degeneration, retinitis pigmentosa, Stargardt, glaucoma, is-
chemic optic neuropathy, and optic atrophy. Given previous experience
with mCNV associated with AMD and high myopia, it seems likely that
these promising new therapies for atrophic AMD may eventually play a
role in the management of chorioretinal atrophy.
5. Neovascular myopic maculopathy
5.1. Concept
Neovascular myopic maculopathy is attributed to a disease origi-
nating in the choroid, which distorts retinal anatomy due to neo-
vascularization in pathologic myopia. Fuch’s spot is defined as any dark
spot in the macula in high myopic patients, the presence of which is
indicative of late stage mCNV. Secondary to CNV, hyperplasia and
migration of RPE cells to the subretinal or intraretinal tissue lead to the
development of this spot. Chorioretinal atrophy will typically develop
around this lesion, over time leading to atrophic myopic maculopathy
(Soubrane, 2008).
5.2. Pathogenesis
Several hypotheses have been proposed to explain the pathogenesis
of mCNV. The presence of lacquer cracks has been associated with a
higher incidence of mCNV, although the development of CNV in pa-
tients with previously-existing lacquer cracks has not been available to
demonstrate this (Ohno-Matsui et al., 2018). Lacquer cracks are also
common in the fellow eyes of patients with mCNV.
Compared to healthy controls, higher VEGF levels have been found
in the aqueous humour of patients with mCNV (Tong et al., 2006). One
study reported a decrease in VEGF and an increase in pigment epithe-
lium-derived factor (PEDF) in the aqueous humour after three injec-
tions of bevacizumab in patients with mCNV (Chan et al., 2008). This
suggests that an imbalance between pro- and anti-angiogenic factors
leads to the development of mCNV, as occurs in other CNV retinal
pathologies, such as neovascular AMD.
There is some evidence to suggest that exposure of RPE cells to
certain extracellular matrix components increases VEGF production,
while disruption of Bruch’s membrane facilitates the emigration of
VEGF to the choroidal space, which can then stimulate CNV develop-
ment (Kwak et al., 2000). Elongation of the myopic eye is usually due to
posterior staphyloma, which may facilitate the development of holes or
a rupture in Bruch’s membrane, as described in patchy chorioretinal
macular atrophy (Ohno-Matsui et al., 2016a) and in myopic macular
atrophy secondary to CNV (Ohno-Matsui et al., 2016b). Exposure of
RPE cells leads to an increase in VEGF, which diffuses through defects
(caused by posterior staphyloma) in Bruch’s membrane, thus promoting
choroidal CNV (Soubrane, 2008). Thinner choroids, characteristic of
high myopic patients (Flores-Moreno et al., 2013), could explain the
low exudation observed in mCNV, observed as subtle leakage on
fluorescein angiography.
5.3. Demographics
In a general population-based study involving 4319 participants,
Fuch’s spot—considered a consequence of mCNV—was present in 3
eyes from 3 patients (prevalence rate, 0.1%). Of the participants in that
Fig. 9. Right (a,b) and left (c,d) eyes from the same myopic patient. Note the progression of the atrophic area in the left eye (c–d) surrounding the central, healed
myopic choroidal neovascularization.
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study with myopic retinopathy, the 3 patients with Fuch’s spot ac-
counted for 1.5% of that subgroup (Liu et al., 2010). In an older (2002)
population-based study performed in Australia, the prevalence of Fuch’s
spot was also 0.1%; interestingly, the mean spherical equivalent
(−11.7 diopters) was higher in these patients (Vongphanit et al.,
2002b). In both of those population studies, high myopic patients with
retinopathy were re-examined 5 years after the initial examination
without any new Fuch’s spots being identified in either study.
The reported prevalence of CNV in eyes with pathologic myopia
ranges from 5.2% (United States) to 11.3% (Japan) (Cheung et al.,
2017). According to one study, 14% of patients have bilateral CNV
(Cohen et al. 1996): in that same study, CNV in patients under age 50
was secondary to high myopia in 62% of cases. In the study by Ohno-
Matsui et al. (Ohno-Matsui et al., 2003), patients with pathologic
myopia were followed for≥ 3 years (mean, 10.8), during which 10.2%
of eyes (n=32) developed CNV; notably, half of those eyes were the
fellow eyes of pre-existing mCNV. In addition, 3.7% of the eyes in the
diffuse CRA group developed CNV during follow-up: 20% in the patchy
CRA group and 29.4% in eyes with previous lacquer cracks. Epide-
miologic studies suggest that mCNV is more common in females (Cohen
et al., 1996; Wong et al., 2014).
5.4. Clinical characteristics and natural history
The most common symptoms of neovascular myopic maculopathy
are sudden, painless vision loss, and central scotoma, usually associated
with metamorphopsia. These symptoms are secondary to the build-up
of fluid and distortion of the retinal anatomy. The fundus in mCNV
presents as a greyish area with hyperpigmented borders, and it is
common to observe small amounts of retinal haemorrhage. Myopic
CNVs are typically classic neovascular membranes or type 2 neo-
vascularization (Freund et al., 2010), mainly located close to the fovea,
although juxtafoveal and extrafoveal localizations are not uncommon.
Peripapillary CNV—which develops around the peripapillary chorior-
etinal atrophy (called periconus CNV)—may also occur.
Characteristically, mCNV has a primary phase during which neo-
vascularization develops slowly, probably due to a thin choroid, which
becomes progressively thinner as the axial length increases (Flores-
Moreno et al., 2013). At this primary stage, CNV activity itself will not
cause long-term vision loss. However, CRA developing around the re-
gressed neovascular lesion—probably secondary to RPE damage—will




FA is the most widely-accepted test to study retinal and choroidal
circulation in myopic patients. The diagnosis of mCNV is confirmed by
FA, which is performed when there is clinical suspicion of mCNV. FA
typically reveals a hyperfluorescent area in early frames indicative of
filling of the neovascular complex, with late leakage into the CNV area,
usually in a classic pattern, which is a sign of neovascular tissue ac-
tivity. Compared to other causes of CNV, leakage in mCNV is sometimes
seen as a subtle change between early and late frames, probably due to
a thinner choroid in mCNV (Flores-Moreno et al., 2013). FA is useful to
identify the presence, type, extension, and activity of the membrane. FA
also helps to differentiate mCNV from other causes of CNV. The dif-
ferential diagnosis in the presence of macular haemorrhage secondary
to lacquer cracks is sometimes challenging, and in this regard FA can be
helpful because in cases with mCNV, there is no leakage on the various
frames of the angiogram.
Leveziel and colleagues have shown that FA is more sensitive than
SD-OCT in new-onset mCNV (Leveziel et al., 2013). In that study, dye
leakage was observed on the FA in 82% of eyes whereas exudation signs
were present on SD-OCT in only 48.6% of eyes. By combining these two
imaging modalities, the sensitivity for the diagnosis of mCNV increases
to 97% (García-Layana et al., 2006) (Fig 10).
5.5.2. Indocyanine green angiography
Indocyanine green angiography (ICGA) is sometimes used as a
complementary test in the diagnosis of myopic CNV, although it is not
very sensitive, as myopic CNV does not show hypercyanescent images
in the angiogram. ICGA provides good visualization of the choroidal
vessels and lacquer cracks and penetrates through blood, pigment and
exudates, which is why it is a valuable complement to other tests in
Fig. 10. Retinography (a), fluorescein angiography (b,c) and spectral-domain optical coherence tomography (d,e) of a highly myopic patient with myopic choroidal
neovascularization (mCNV). These two techniques have a combined sensitivity for the diagnosis of mCNV of up to 97% (García-Layana et al., 2006).
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diagnosing difficult cases of mCNV. It is particularly useful as a com-
plementary test in myopic patients with dense macular haemorrhages,
helping to confirm mCNV located below the haemorrhage (Fig 11).
5.5.3. Fundus autofluorescence
FAF provides good visualization of lipofuscin contained in the RPE.
This imaging technique also provides a very good delimitation of CRA,
mostly patchy atrophy. However, FAF cannot be used to diagnose new-
onset mCNV. On FAF, two different patterns—a hyperautofluorescent
pattern and a patchy pattern—have been identified in eyes with mCNV.
After treatment with intravitreal ranibizumab, the course of the disease
and prognosis differ depending on which pattern is observed. The hy-
perautofluorescent pattern is associated with a better BCVA gain and
fewer atrophic changes while the patchy pattern implies a worse post-
treatment prognosis. The hyperautofluorescent pattern is more
common, as evidenced in the study by Parodi et al., who observed this
pattern in two of the three cases (Parodi et al., 2015) (Fig 7).
5.5.4. Optical coherence tomography
OCT is a non-invasive technique that has been successfully used to
diagnose and monitor treatment response in mCNV. SD- and SS-OCT
both provide a good resolution of the anatomy in high myopic eyes,
including the retina, choroid, sclera and, even the retrobulbar elements,
such as orbital fat.
Three different stages of CNV have been identified based on the
characteristics observed on OCT: active lesion, scar, and atrophic stage
(Fig. 12). Active mCNV appears as a dome-shaped elevation with a
hyperreflective component above the RPE; given that most cases of
mCNV are type 2 CNV, this elevation is associated with retinal thick-
ening and intraretinal fluid, which appears as retinal cysts and sub-
retinal fluid on OCT imaging (Leveziel et al., 2013; Ohno-Matsui et al.,
2016c). Interruption of the external limiting membrane (ELM) or lack
of ELM visibility correlate with the leakage area observed on FA, and
for this reason a missing or interrupted ELM is a good indicator of CNV
activity, which is useful for both diagnosis and follow-up (Battaglia
Parodi et al., 2016). On OCT imaging, the scar stage is characterized by
hyperreflectivity in the inner surface of the CNV, with attenuation of
the tissue below. In this stage, there is usually a migration of pigment
from the RPE, resulting in a Fuch’s spot. During the atrophic stage, the
neovascular lesion flattens and CRA develops in the CNV area, resulting
in a decrease in BCVA. Reflectivity increases below the atrophic area
due to a decrease in RPE pigmentation (Baba et al., 2002) (Fig 12).
5.5.5. Optical coherence tomography angiography (OCTA)
OCTA is a novel, dye-less, non-invasive technique based on OCT
technology that can detect movement—attributed to the flow of ery-
throcytes inside the vessels—between scans. OCTA provides high-
quality layered images of the retina and choriocapillaris. Simultaneous
b-scans show the exact area of flow and the segmentation, which helps
to reduce interpretation errors.
Myopic CNV images on the OCTA scan are represented as two dif-
ferent subtypes: 1) a well-organized, interlacing pattern, suggesting a
mature membrane, and 2) a small, disorganized vascular loop subtype,
indicative of an immature lesion (Bruyere et al., 2017). However, not
all authors agree about these patterns. Several authors have failed to
identify any clear pattern, describing the lesions as irregular, with poor
margin definition, central capillaries, and without any well-defined
centre (Cheng et al., 2017; Querques et al., 2016). The neovascular
complex appears in the avascular outer retinal slabs of OCTA. This
pattern is clearly attenuated after anti-VEGF therapy, showing a de-
creased flow signal or even a complete regression of the neovascular
vessels (Cheng et al., 2017).
The sensitivity of OCTA to diagnosis mCNV is high (90%–94.1%) as
is the specificity (93.75%) (Bruyere et al., 2017; Miyata et al., 2016;
Querques et al., 2016). However, identifying the neovascular complex
in patients with large CRA areas, bad fixation, and very long axial
length remains challenging. Despite the advantages of OCTA, this
imaging technique has several limitations, mostly in eyes with a long
axial length or a deep posterior staphyloma. Layer segmentation is often
difficult in these cases, but is crucial to image interpretation. Un-
fortunately, the images are difficult to interpret in many cases due to
motion, projection, and masking artefacts, in addition to a low fixation
in many high myopic patients. Consequently, at present, OCTA should
be performed in combination with SD-OCT or SS-OCT, using B-scan or
Fig. 11. Fundus photography of a highly myopic patient with macular haemorrhage (a). Fluorescein angiography cannot rule out the presence of an active neo-
vascular membrane (b, c). On indocyanine green angiography, no choroidal neovascularization is visible (d, e) and therefore the patient was not treated. Clear
improvement is evident one month later(f).
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en face mode, plus FA to check for the presence of CNV activity. In cases
where FA or ICGA is absolutely or relatively contraindicated OCTA is
preferred to FA or ICGA (Kashani et al., 2017).
OCTA is a promising imaging technique in retinal vascular diseases,
and it will undoubtedly help physicians better understand the physio-
pathology of these diseases. However, the technology requires more
development to improve the overall quality of the image, to reduce
artefacts, and to obtain better field-of-view and segmentation, espe-
cially in high myopic eyes with thin choroids, thin sclera, and posterior
staphyloma. Although OCTA will not replace FA or ICGA, it has already
decreased the routine use of those techniques (Fig. 13 and 14).
OCTA may be of value in several conditions in which it is difficult to
make an accurate differential diagnosis. One example is the multifocal
choroiditis (MFC)-punctate inner choroidopathy (PIC) spectrum, which
usually affects young myopic women who develop focal deep retinal
and choroidal inflammation and have a tendency to develop CNV le-
sions. In contrast to mCNV, MFC-PIC lesions tend to be multiple, bi-
lateral, with a yellow-white colouring initially, and they may induce an
anterior chamber reaction. FAF can accurately detect active lesions. On
FA, these lesions usually show optic disc staining, which is not found in
highly myopic patients. It is sometimes difficult to distinguish between
active inflammatory lesions and CNV because the clinical signs and
multimodal imaging findings are similar(Astroz et al., 2018). In this
regard, OCTA is highly valuable due to its capacity to detect CNV le-
sions, which can be seen as an organized high-flow network located in
the outer retinal and choriocapillaris images, and to differentiate
between CNV and active inflammatory lesions, which show no flow on
OCTA (Astroz et al., 2018).
5.6. Treatment
5.6.1. Historical treatments
In patients with mCNV, final BCVA tends to be poor due to the
development of CRA around the regressed membrane (Hayashi et al.,
2010). Indeed, this poor outcome explains the strong interest in finding
an effective treatment.
In the past, the mCNV was surgically resected based on the notion
that removal of the neovascular complex would help to maintain vision
without damaging the RPE since most mCNVs are located above the
RPE (type 2 CNV). For many reasons—scar formation, central scotoma,
recurrences, and the long learning curve and invasive nature of the
surgical procedure—this complex surgical technique was abandoned
(Neelam et al., 2012).
In subfoveal mCNV, the classic treatment approach was macular
translocation, whose objective was the transfer of the foveal neuro-
sensory retina to another location with a (theoretically) better RPE-
Bruch membrane-choriocapillaris complex. In this complex and difficult
surgical technique, the retina was rotated around the optic nerve and
the fovea replaced (Soubrane, 2008). However, nowadays, this ap-
proach is rarely used.
Laser photocoagulation has been used to treat mCNV, but this
treatment approach has important limitations. For example, in
Fig. 12. Dome-shaped elevation with hyperreflective component above the retinal pigment epithelium suggesting active choroidal neovascularization (CNV) (a,b);
The scar stage is seen on optical coherence tomography, indicated by hyperreflectivity of the inner surface of the CNV with attenuation of the tissue below (c,d).
Reflectivity increases below the developing atrophic areas, with a flattening of the lesion (e,f).
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subfoveal CNV, the treatment caused central scotoma and visual loss
(Soubrane, 2008). Due to the expansion of the CRA and a high recur-
rence rate, laser photocoagulation has largely been abandoned (Neelam
et al., 2012), except in certain well-defined cases such as extrafoveal or
juxtafoveal lesions (Fig 15).
5.6.2. Photodynamic therapy (PDT)
In the VIP clinical trial (Verteporfin in PhotodynamicTherapy (VIP)
Group Study, 2001), PDT was compared to sham treatment in patients
with mCNV, resulting in a greater improvement in BCVA. In that trial,
BCVA had stabilized at the 12-month follow up in 72% of patients
treated with PDT versus only 44% of the placebo group, with the PDT
group twice as likely to present a 5-letter improvement in BCVA.
However, at the 24-month follow-up, there were no inter-group dif-
ferences in BCVA stabilization, although the distribution of changes in
BCVA indicate that the PDT group had better outcomes at month 24
(Blinder et al., 2003). Theoretically, PDT dissipates less laser energy to
the RPE and neurosensory retina, and thus there is less tissue destruc-
tion and scar expansion than occurs with laser photocoagulation
(Blinder et al., 2003; Verteporfin in Photodynamic Therapy (VIP) Group
Study, 2001).
Visual prognosis after PDT in mCNV patients depends on the age at
diagnosis, with worse results in older patients (Coutinho et al., 2011;
Ergun et al., 2004; Montero and Ruiz-Moreno, 2003). A prospective
study of patients diagnosed with mCNV treated by PDT found that
BCVA was significantly better in younger patients during the first two
years of follow-up, although this difference did not remain significant
after longer follow-up (Ruiz-Moreno et al. 2008). The health of the
chorioretinal tissue may have a large effect on BCVA after PDT treat-
ment, which explains why younger patients with better initial BCVA
may develop less CRA and scarring. Age may also play a role in indu-
cing choriocapillaris sclerosis and RPE defects, as has been reported for
CRA (Curcio et al., 2000). In a previous study conducted by our group,
most of the patients who underwent PDT achieved stabilization or
improvement in BCVA, with a (non-significant) trend towards im-
provement during the four-year follow-up. In that study, the number of
lines gained was positively correlated with the initial size of the neo-
vascular lesion (Ruiz-Moreno et al. 2008). Coutinho et al. evaluated
long-term safety and efficacy of PDT, finding that, at 5-year follow-up,
two-thirds of patients improved or stabilized BCVA (Coutinho et al.,
2011).
The location of the mCNV has a large influence on final BCVA after
PDT. Juxtafoveal lesions have a relatively smaller chorioretinal atrophy
area and better BCVA compared to subfoveal lesions (Hayashi et al.,
2011). Several authors support the use of PDT to treat juxtafoveal le-
sions, but PDT carries a substantial risk of increasing the size of the
CNV, as studies have shown that a juxtafoveal CNV can become a
subfoveal CNV after PDT (Bandello et al., 2003). Another prognostic
factor is the pretreatment degree of myopia. Kwak et al. found that eyes
with longer axial lengths and greater chorioretinal degeneration may
express less VEGF and consecutively experience less CNV growth (Kwak
et al., 2000). Several studies have corroborated this finding, showing
that more myopic eyes obtain better final BCVA (Pece et al., 2006);
nevertheless, several other studies have failed to confirm those findings
(Ergun et al., 2004; Montero and Ruiz-Moreno, 2003).
PDT induces overexpression of VEGF and other hypoxia-induced
factors, leading to a recurrence in the neovascular lesion and thus the
need for retreatment. Combining PDT with intravitreal corticosteroids
may reduce the number of retreatments needed. Unfortunately, evi-
dence to support this approach is not strong due to the small sample
sizes in the studies performed to date. Marticorena et al. reported better
outcomes in 12 eyes from 12 patients treated with PDT plus intravitreal
triamcinolone (Marticorena et al., 2006). By contrast, Chan et al. found
no differences between patients treated with PDT alone and those who
received PDT combined with intravitreal triamcinolone (Chan et al.
2007), although those authors did find that a subgroup of patient-
s—those with a larger CNV and lower initial BCVA—may benefit from
the combination therapy. Side effects from intravitreal triamcinolone,
such as cataract formation and an increase in intraocular pressure, limit
the use of this combined approach to elderly patients, who usually have
worse BCVA and a poorer response to PDT, or to patients with frequent
recurrences, or those with large mCNV lesions (Chan et al., 2007).
Fig. 13. Fundus photography of the right eye of a highly myopic patient (a). Optical coherence tomography (OCT) angiography shows normal superficial and deep
plexi (b, c). A deeper section just above the retinal pigment epithelium shows myopic choroidal neovascularization (d). Flow is confirmed by OCT b-scans inside the
hyperreflective lesion (e).
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When PDT was first developed, it was considered an important
advance because it was substantially more effective than other treat-
ments available at the time. However, the emergence of anti-VEGF
therapy, which obtains better visual outcomes than PDT, has relegated
PDT to use as a second-line treatment for mCNV (Silva, 2012).
5.6.3. Anti-VEGF treatment
5.6.3.1. Bevacizumab. Several studies have reported excellent results
with intravitreal anti-VEGF agents for the treatment of CNV secondary
to AMD (Brown et al., 2006; Rosenfeld et al., 2006). Based on the
results of those studies and considering the high VEGF levels in eyes
with mCNV, together with the known role of VEGF in mCNV
pathogenesis (Tong et al., 2006), researchers and clinicians began to
investigate the use of anti-VEGF drugs in mCNV. Nguyen et al. were the
first to report good results in patients previously-treated with PDT for
mCNV (Nguyen et al., 2005). In that study, the researchers
administered intravenous bevacizumab (5mg/kg), which resulted in
an improved BCVA in both patients. In a small, prospective study, Arias
et al. administered intravenous bevacizumab in 17 eyes with mCNV,
obtaining good results at six months of follow-up: 41% of patients
increased at least one line, and 17% increased more than six lines. The
patients received a mean of one intravitreal injection during follow-up-
(Arias et al., 2008).
Other studies with longer follow-up (≥12 months) of follow up,
using a similar initial protocol (3 monthly intravitreal injections of
1.25mg of bevacizumab) have successfully improved BCVA without
any systemic or ocular side effects (Gharbiya et al. 2009; Ruiz-Moreno
et al. 2009b; Chan et al. 2009). Due to the intrinsic characteristics of
mCNV, the loading dose used in those studies (three monthly injections)
is somewhat controversial. As a result, other authors have preferred to
Fig. 14. Optical coherence tomography (OCT) b-scans of a highly myopic patient suffering from choroidal neovascularization (CNV). A hyperreflective lesion is
accompanied by subretinal fluid (a–d). Fluorescein angiography (FA) confirm the presence of a classic CNV (e, f). OCT angiography shows a neovascular lesion with
the exact same shape as seen on FA (g), with flow represented by warm colours (h).
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use only a single initial injection, with retreatment as needed, with
good outcomes at one-year (Ikuno et al. 2009; Wu and Chen 2009).
Ruiz-Moreno et al. retrospectively evaluated 107 eyes with subfoveal or
juxtafoveal CNV treated with one initial intravitreal dose of bev-
acizumab (1.25mg) followed by a pro re nata regimen (PRN), finding
that BCVA increased from 0.72 to 0.53 (logMAR, p= 0.001) after one
year of follow-up. In addition, 45% of eyes achieved a BCVA better than
20/65, and 30% gained 3 or more lines (15 ETDRS letters). However,
40% of the eyes required retreatment, with a mean of 0.8 ± 1.3 re-
injections. Outcomes were better in younger patients (< 50 years). The
gain in BCVA occurred mainly during the first 3 months, after which
vision stabilized. There were no differences between patients with or
without previous PDT treatment, and the pattern of visual gain was
comparable in both groups (Ruiz-Moreno et al. 2010). The results of the
aforementioned studies suggest that a single intravitreal injection of
bevacizumab with a PRN follow-up may be the treatment of choice for
mCNV.
Studies that have performed long-term follow-up of patients treated
with bevacizumab have reported good outcomes. One retrospective,
non-randomized, multicenter study followed 92 eyes for 4 years. The
initial anti-VEGF protocol (either 1 or 3 intravitreal injections) was left
to the clinical judgment of the investigators, with PRN as the follow-up
protocol. The main outcome measure was change in BCVA. BCVA
(ETDRS letters) was 46.1 at baseline (standard deviation [SD], 16.8); at
months 12, 24, 36, and 48, the BCVA results were, respectively, 55.5
(18.6), 50.1 (20.1), 54.2 (21.9), and 53.1 (22.5), all of which were
statistically significant. The mean number of injections was 4.9 (5.4).
Neither the spherical equivalent nor the number of injections affected
Fig. 15. Highly myopic patient who underwent laser photocoagulation to treat myopic choroidal neovascularization. The area of chorioretinal atrophy grew con-
siderably throughout the follow-up.
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the final outcome (Ruiz-Moreno et al. 2013a,b). Another study with a
longer follow-up retrospectively evaluated patients who received a
mean of 3.3 (2.3) injections. During the first 3 years of follow-up, BCVA
improved and stabilized; however, this improvement was no longer
statistically significant at years 4, 5, and 6 of follow-up (Ruiz-Moreno
et al. 2015).
Most of the patients in the studies conducted to date to evaluate
anti-VEGF in mCNV were previously treated with PDT. As a result, it is
difficult to extrapolate the findings from those studies to treatment-
naïve mCNV patients. However, some studies have performed a sub-
analysis to compare eyes with and without previous PDT, showing
better outcomes in eyes without previous PDT (Ruiz-Moreno et al.
2009a; Arias et al. 2008; Chan et al. 2009).
5.6.3.2. Ranibizumab
5.6.3.2.1. Clinical trials. The REPAIR trial was a prospective, phase
II, multicentric study of 65 treatment-naïve mCNV patients diagnosed
by SD-OCT and FA. Patients received a median of 3 injections during
the 12-month follow-up period. Median time to retreatment was 2
months. The mean improvement in ETDRS letters was 13.8 at the 12-
month follow up, with the largest improvement observed after the first
month (gain of 8.7 letters). BCVA improved in most (86%) of the
patients, with a mean increase of ≥15 letters in 36.9% of eyes. Central
retinal thickness (CRT) decreased significantly—by a mean of
−135 μm; similar to the BCVA outcomes, the largest decrease in CRT
occurred during the first month (mean, −109 μm) (Tufail et al., 2013).
RADIANCE was a phase III, double-masked, randomized controlled
trial (RCT) of 277 patients with mCNV. Patients were allocated one of
three different treatment arms, as follows: 1) ranibizumab guided by
BCVA stabilization criteria, 2) ranibizumab guided by disease activity
criteria, or 3) verteporfin PDT, with ranibizumab allowed from month 3
onwards. The primary objective was to demonstrate the superiority of
ranibizumab to PDT at month 3. The aims of the trial were successfully
met as all three groups showed significant improvement, with the
greatest gains in the ranibizumab groups: +10.5 (± 8.2) ETDRS letters
(group 1), +10.6 (± 7.3) (group 2), and +2.2 (± 9.5) (group 3) (both
p < 0.00001). The secondary objective of that study was to demon-
strate the noninferiority of ranibizumab guided by disease activity
criteria versus BCVA stabilization criteria at month 6. The results
showed no differences between those groups in mean change in BCVA:
group 2, +11.7 (± 8.2) vs. group 1, +11.9 (± 8.8); p < 0.00001). At
12 months’ follow-up, the percentage of eyes in each group gaining
≥15 letters was as follows: 53.3% (group 1), 51.7% (group 2), and
32.7% (group 3). The decrease in CRT observed in groups 1 and 2 was
maintained from month 3 (−61 μm and −77.6 μm, respectively) to
month 12 (−66.6 μm and −71.3 μm, respectively). In the PDT
treatment group, the mean thickness decreased progressively, from
−12 μm at month 3 to −60.8 μm at month 12. The mean number of
ranibizumab injections was 4.6 in group 1, 3.5 in group 2, and 2.4 in
group 3. The authors concluded that intravitreal ranibizumab provides
better outcomes in mCNV compared to initial PDT treatment followed
by intravitreal ranibizumab (Wolf et al., 2014).
The RADIANCE trial showed that patients treated with intravitreal
ranibizumab obtained significantly greater improvements on many
quality of life (QoL) parameters than PDT-treated patients (Wong et al.,
2015). DSM (diagnosed by OCT) was present in 18% of the patients in
the RADIANCE trial, and ranibizumab was equally effective in eyes with
or without DSM (Ceklic et al., 2014). Those findings underscore the
importance of diagnosing DSM in eyes with suspected mCNV, as such
eyes are more likely to respond to anti-VEGF therapy, although sub-
retinal fluid may remain secondary to this inward bulge.
5.6.3.2.2. Clinical studies. Numerous uncontrolled, non-randomized
studies have also demonstrated good response to ranibizumab in
patients with mCNV (Table 1). One study reported short-term
improvement in BCVA from the first month after a single dose of
ranibizumab, with 31% of patients achieving an increase of 3 or more
lines and with most patients maintaining significant gains in BCVA at 3
and 6 months (Silva et al., 2008). Clinical studies with ≥12 months of
follow-up confirm the safety and efficacy of ranibizumab, which
requires only a limited number of injections (Lorenzo et al., 2011;
Monés et al., 2009; Silva et al., 2010; Wong et al., 2015). Although
ranibizumab improves functionality in patients previously treated with
PDT, the available data suggests that PDT-naïve patients have better
outcomes (Lorenzo et al., 2011; Silva et al., 2010).
Kung et al. (Kung et al., 2014) retrospectively compared initial
dosing regimens of ranibizumab. In one group (25 eyes), patients re-
ceived a single initial injection while a second group (21 eyes) received
three consecutive monthly injections. Both groups were re-treated if
active disease remained. Overall, the second group required more in-
jections (mean, 3.57 vs. 2.32; p < 0.001). However, the retreatment
rate was lower in the group that received a loading dose of 3 monthly
injections (p < 0.037). At the 12-month follow-up, there were no
differences in BCVA or CMT between the groups, leading the authors to
conclude that three initial injections are not necessary but that close
follow-up is crucial (Kung et al., 2014). Similar results were reported in
other studies that performed the same comparison (i.e., single initial
ranibizumab injection vs. three consecutive monthly injections)
(Lorenzo et al., 2011; Monés et al., 2009; Silva et al., 2010; Wong et al.,
2015). Based on the current evidence, it appears that a single initial
injection should be the initial treatment protocol, similar to the pro-
tocol for bevacizumab.
Calvo-González et al. prospectively evaluated patients who received
a loading dose of three ranibizumab injections (mean follow-up, 15.9
months), finding that the BCVA improved by 7.8 ETDRS letters after the
first injection and by 12.6 ETDRS letters after the third monthly in-
jection. This improvement was maintained throughout the follow-up
period. Those findings led the authors to recommend a loading dose of
three monthly injections (Calvo-Gonzalez et al., 2011).
Lalloum et al. prospectively evaluated 32 eyes from 32 patients
treated with intravitreal ranibizumab (mean follow-up, 17 months),
finding an increase of ≥3 lines in 46.8% of patients and a mean de-
crease of 103 μm in CRT (on SD-OCT) (Lalloum et al., 2010).
Long-term studies have reported heterogenous results after the
second year, with some studies reporting that BCVA is stable or may
even improve during the third year (Franqueira et al., 2011) while
other studies have reported a decrease in BCVA over the course of
follow-up (39 months) (Cohen et al. 2015). These contrasting findings
may be due to the close follow-up performed by Cohen et al. and to
differences in the number of injections over time.
Several studies have compared ranibizumab to bevacizumab in
patients with mCNV. Gharbiya et al. performed a RCT to compare
outcomes (visual acuity, CRT, and number of intravitreal injections)
(Gharbiya et al., 2010). At 6 months of follow-up, the ranibizumab
group had obtained an increase of 17.31 letters versus 15.87 letters in
the bevacizumab group, a non-significant difference (p= 0.68). In both
groups CRT decreased significantly (206 μm and 185 μm, respectively)
without any statistically significant differences between the groups
(p= 0.72). Similarly, no between-group differences were observed in
the mean number of injections (2.81 vs. 2.44, respectively). These
findings led the authors to conclude that, overall, there appear to be no
significant differences in treatment outcomes (BCVA, CRT, number of
injections) between ranibizumab and bevacizumab after 6 months of
follow up in patients treated for mCNV (Gharbiya et al., 2010). A
follow-up study confirmed the lack of significant differences between
the two groups (Ruiz-Moreno et al. 2015; Ruiz-Moreno et al. 2013a,b).
Yoon et al. identified several prognostic factors for visual outcome
(BCVA and vision improvement) after treatment with bevacizumab or
ranibizumab injections in patients with mCNV. They found that the
following factors were predictors of good treatment outcomes were:
baseline BCVA, peripapillary choroidal atrophy size, and presence of
lacquer crack extending to the fovea (Yoon et al., 2012).
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5.6.3.3. Aflibercept
5.6.3.3.1. Clinical trials. The MYRROR study was an international,
phase III, multicenter, randomized, double-masked, sham-controlled
study conducted in five different countries (Japan, Hong Kong,
Republic of Korea, Singapore, and Taiwan) to evaluate the efficacy,
safety and tolerability of aflibercept in patients with mCNV. Patients
were randomized (3:1 ratio) to receive aflibercept or sham treatment.
Follow up was performed every 4 weeks for 48 weeks, with retreatment
in cases with active CNV. The primary and secondary endpoints were,
respectively, mean change in BCVA at 24 weeks and the proportion of
patients with an increase of≥15 ETDRS letters at weeks 24 and 48. The
mean BCVA gain in the treatment group was 12.1 letters versus a loss of
2 letters in the sham group (p < 0.0001). The treatment group
received a mean of 2.9 intravitreal injections. Compare to the sham
group, a higher percentage of patients in the aflibercept group gained
≥15 letters at both week 24 (38.9% vs. 9.7%; p=0.0001) and week 48
(50.0% vs. 29.0%; p= 0.0308). Moreover, these significant differences
were achieved even though patients in the sham group received an
aflibercept injection after week 24. No differences were observed when
patients were stratified by age or ocular axial length. Intravitreal
aflibercept was generally well tolerated, with a good safety profile.
The authors concluded that aflibercept is a safe and efficacious
treatment option for mCNV, requiring only a limited number of
injections to obtain good anatomic and functional results (Ikuno
et al., 2015).
5.6.3.3.2. Clinical studies. Several studies have evaluated
aflibercept in mCNV. Two studies reported good safety and functional
outcomes at 12 months of follow-up after a mean of 2 aflibercept
injections using a PRN regimen for retreatment (Korol et al., 2016;
Pecce and Milani, 2016). Those studies found that younger patients
(< age 50) needed fewer injections and tended to have a greater
improvement in BCVA (Bruè et al., 2016; Pecce and Milani, 2016). The
reason attributed to these better outcomes in younger patients is that
they tend to have a better functioning RPE, which may more effectively
inhibit CNV growth compared to older patients, whose RPE may not
function as well.
Brue et al. evaluated 38 naïve mCNV patients treated with in-
travitreal aflibercept and followed for ≥18 months. Overall, BCVA
improved from 0.69 to 0.15 logMAR at 18 months (p < 0.01) and the
mCNV fully resolved in 55% of patients after a single aflibercept in-
jection (Bruè et al., 2016).
Myopic CNV is a leading cause of visual impairment in high myopic
patients. Given the potentially devastating consequences of this disease,
a prompt diagnosis is crucial. FA and OCT are essential complementary
tests when high myopic patients complain of metamorphopsia or de-
creased BCVA. However, clinicians should pay close attention to
symptoms in highly myopic patients given that these patients often
present with complaints well before any clinical signs can be detected
on any test. It seems evident that OCTA will play a fundamental role in
the diagnosis of mCNV in the future due to its noninvasive nature and
its rapid image capture. The current treatment of choice for mCNV is
anti-VEGF treatment, starting with a single dose and PRN follow-up.
6. Myopic traction maculopathy
6.1. Vitreous characteristics in myopic patients
The vitreous cortex and the inner limiting membrane (ILM) form the
vitreomacular interface (VMI). The ILM is composed of collagen types
IV, VI and VIII, associated with glycoproteins. This membrane acts as a
basal membrane for retinal Müller cells. The vitreous cortex consists
primarily of a dense matrix of collagen that follows a lamellar pattern.
VMI attachments are tighter at the vitreous base, optic disc, vascular
arcades and fovea; this strong attachment helps to explain numerous
vitreoretinal diseases, especially in highly myopic patients, where
outpouching of the posterior pole in cases with staphyloma can induce
posterior vitreous detachment. Advancements in imaging technolo-
gy—especially deep penetration OCT—provide many details about the
posterior precortical vitreous pocket (PPVP), a physiological lacuna
located in the posterior pole of healthy eyes. The PPVP is confined
between the cortex in contact with the ILM and the vitreous gel, and it
can simulate a fake posterior vitreous detachment (PVD), which is often
discovered during vitreoretinal surgery in these patients (Itakura et al.,
2014; Itakura et al., 2013).
Vitreous liquefaction, PVD, and PPVP are more prevalent in myopic
eyes. PVD is typically diagnosed at a younger age in these patients
compared to the general population. Indeed, the prevalence of PVD in
myopic eyes is 38%, with greater axial length associated with early
development of PVD (Akiba, 1993). Kishi et al., using SD-OCT and SS-
OCT, found a prevalence rate of 43.2% for PVD in highly myopic eyes,
which is five times higher than in emmetropic eyes (Kishi, 2014). OCT
can be useful to correctly characterize the VMI in myopic patients given
that biomicroscopy overestimates the prevalence of complete PVD be-
cause the posterior cortex may still be attached to the retina despite
clear visualization of a Weiss ring (Lorenzo Carrero, 2012).
Using scanning electron microscopy, Kishi et al. were the first to
describe the presence of vitreous cortex remnants in cadaver eyes with
visible PVD (Kishi et al., 1986). In a more recent study, those authors
used SS-OCT imaging to identify the presence of remnants in 6.7% of
non-myopic and 37.7% of myopic eyes (Itakura et al., 2014). SS-OCT
plays an important role because it provides a basis for the interpretation
and diagnosis of several VMI disorders in highly myopic patients.
6.2. Epiretinal membrane
6.2.1. Definition / etiopathology
Epiretinal membranes (ERM) are described ophthalmoscopically as
a reflective, relatively opaque layer on the surface of the retina. These
membranes may mimic the appearance of cellophane and can cause
traction by inducing folding of the retinal surface. On OCT images, ERM
is easily identified as a hyperreflective band located over the ILM. ERMs
are found in 11.3%–45.7% of highly myopic patients (Ripandelli et al.,
2012; You et al., 2014). They tend to be multilayered, with a pre-
dominant glial component (Kampik, 2012). Two ERM patterns (type 1
and 2) can be observed on electron microscopy. Depending on the
pattern, the surgical approach may vary. In type I ERM, a sheath of type
II collagen is present between the ILM and the proliferating cells that
Table 1
Published papers in patients treated with ranibizumab injections in myopic CNV and a minimum follow-up of 12 months.
Author Design Year Follow-up (months) N Mean age Mean BCVA change(ETDRS letters) Mean number of injections
Monés Prospective 2009 12 23 51.1 +9.5 1.5
Silva Prospective 2010 12 34 54 +8 3.6
Lalloum Prospective 2010 17 32 57 +9.5 3
Lorenzo Retrospective 2011 12 29 56.8 +8.9 1.4
Clavo-González Prospective 2011 15.9 67 59 +12 4.2
Franqueira Retrospective 2012 36 40 55 +8 7.6
Cohen Retrospective 2015 39.3 51 64 +7.6 3.5
J. Ruiz-Medrano et al. Progress in Retinal and Eye Research 69 (2019) 80–115
100
form the ERM. In type II ERM, cells proliferate directly over the ILM
with little to no collagen, acting as a cleavage plane (unlike type I)
(Kampik, 2012). Cell lineages in this pathology do not seem to differ
between VTM and idiopathic ERM, although some studies report a
marked presence of glial components (Kampik, 2012).
Previously, it was hypothesized that mini-retinal breaks develop
after PVD, inducing proliferation of fibroblasts, astrocytes, and glial
cells (Vinores et al., 2016). However, more recent hypotheses suggest
that ERM proliferate from residual vitreous remnants that remain on
the surface of the retina after a complete or incomplete PVD and grow
over the ILM (Gupta et al., 2011; Gandorfer et al., 2009). Longer eyes in
highly myopic patients, especially those with posterior staphyloma,
tend to develop PVD earlier, which is often incomplete due to schisis of
the posterior vitreous, thus leaving cortex remnants tightly attached to
the ILM. These remnants, together with Müller cell activation, induce
the development of ERM (Foos 1977; Snead et al., 2008; Lorenzo
Carrero, 2012; Kampik, 2012).
6.2.2. Treatment
Surgery is required to remove an ERM, but this may prove chal-
lenging in highly myopic patients due to their usual anatomical char-
acteristics (i.e., longer axial length), especially in cases with posterior
staphyloma or posterior pole atrophy that may impede visualization.
The type I ERM pattern theoretically requires a double ERM-ILM
peeling, given that a simple ERM peeling may leave collagen residue on
the surface of the ILM, which could induce recurrence. By contrast, type
II ERM can be managed with a simple ERM peeling, as there is no
collagen between the ERM and the ILM (Blanco Teijeiro et al., 2015).
Nevertheless, ILM removal remains controversial despite the proven
reduction in recurrence rates after double peeling (Shimada et al.,
2009).
6.3. Myopic traction maculopathy / myopic foveoschisis
6.3.1. Definition / etiopathology / classification
Myopic traction maculopathy (MTM) is an umbrella term that en-
compasses a wide spectrum of related disorders, including vi-
treomacular traction (VMT) in highly myopic patients, myopic fo-
veoschisis, and myopic MH. Retinoschisis affects from 8% to 34% of
patients with posterior staphyloma (Baba et al., 2003; Benhamou et al.,
2002). The presence of posterior staphyloma in highly myopic patients
plays a key role in the subsequent development of MTM, as the retina in
these cases cannot match the scleral outpouching of the posterior pole
due to its greater rigidity. This rigidity may be caused by numerous
factors, including vascular rigidity, the presence of ERM or VMT syn-
drome, cortical vitreous remnants, or simply the fact that the retina, its
vessels, and the ILM seem to be less elastic than the surrounding tissues
(Vanderbeek and Johnson, 2012; Ikuno et al., 2005; Shimada et al.
2013).
Myopic foveoschisis can be diagnosed ophthalmoscopically in cer-
tain cases, but OCT examination is essential to establish the correct
diagnosis and for follow-up purposes. Myopic foveoschisis involves a
progressive separation of retinal layers, which remain connected by
Müller cells—a process known as myopic foveoschisis, which was first
described by Phillips in 1958 (Phillips, 1958). Ohno Matsui’s group
classified this disease into five different categories based on location
and the size of the affected area, ranging from no apparent foveoschisis
(S0) to complete macular involvement (S4) (Shimada et al., 2013)
(Table 2).
Others have classified myopic foveoschisis according to the location
of the splitting within the retina into inner (affecting inner plexiform
layer, ganglion cell layer, and retinal nerve fibre layer), outer (affecting
outer plexiform and outer nuclear layers) or inner + outer (Fujimoto
et al., 2010; Ceklic et al., 2017). The growth of a posterior staphyloma
generates an evident external traction, which in combination with the
factors that cause retinal rigidity and with the potential presence of
tractions caused by vitreous adherences, lead to the development and
progression of the disease.
6.3.2. Course of disease
Although myopic foveoschisis may remain stable (including stable
BCVA) during long periods, it is considered to be a slowly-progressive
condition (Gaucher et al., 2007). However, a few cases of spontaneous
improvement have been reported (Hoang et al., 2016). Several studie-
s—all of which reached similar conclusions—have described the nat-
ural course of this disease. Gaucher et al. studied 29 eyes from 23 highly
myopic patients with foveoschisis, both with and without previous
surgery, finding that 20 of those eyes suffered a BCVA loss during the
nearly three-year (31.2 months) follow-up period (Gaucher et al.,
2007). In a more recent study, Shimada et al. (Shimada et al., 2013)
analyzed 207 highly myopic eyes from 168 consecutive patients (> 3
years of follow up), finding that BCVA improved in only 3.9% of the
eyes, with the improvement attributable either to complete PVD or to
spontaneous traction release. By contrast, 24 of the 207 eyes (11.6%)
progressed, with a decrease in BCVA during follow-up. These results led
the authors to conclude that eyes with more severe macular involve-
ment had higher progression rates, based on the finding that eyes with
less extensive foveoschisis progressed in only 6.7% of cases versus
42.9% of the eyes with more extensive foveoschisis (Shimada et al.,
2013).
The progressive nature of this disease may lead to foveal detach-
ment and full-thickness MH in more severe cases (Shimada et al., 2013;
Forte et al., 2007), leading to a substantial decrease in BCVA. The most
severe potential complication is development of a MH, which may lead
to retinal detachment in patients with persistent traction over the
margins of the MH.
6.3.3. Treatment
6.3.3.1. Approach. In some cases of MTM, both the macular anatomy
and BCVA remain stable. In eyes with stable disease, the most widely
accepted approach is conservative treatment. However, due to the
progressive nature of MTM, routine follow-up is mandatory, with
surgery being the only option in patients whose condition worsens.
The optimal time to perform surgery in these patients has long been a
topic of intense debate, and even today this question remains
controversial.
Traction in the vitreomacular interface in the context of deep sta-
phylomas causes retinal cleavage. While there seems to be no evidence
linking the presence of VMT syndrome or ERM to final visual outcomes,
damage to the ellipsoid layer or the emergence of full-thickness MH can
both lead to worse functional and anatomical results.
Several reports suggest that preoperative BCVA is one of the key
predictors of final BCVA in these patients. Lehman et al. found that
preoperative BCVA was the only predictor of postoperative BCVA,
concluding that the lower the preoperative BCVA, the greater the
postoperative improvement in BCVA (Lehmann et al., 2017). While
some authors have not found any correlation between foveal status and
final BCVA, others report that the presence of foveal detachment
(versus no foveal detachment) leads to a statistically greater improve-
ment in BCVA, which may be explained by regeneration of the photo-
receptors after foveal re-attachment (Kumagai et al., 2010). In this same
Table 2





S3 Foveal but not entire macula
S4 Entire macula
Shimada et al. Am J Ophthalmol 2013
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line of investigation, Figueroa et al. performed vitrectomy surgery on
30 eyes with MTM (mean follow-up, 33.8 months), finding that gains in
BCVA were more likely in patients with preoperative BCVA of 20/63 or
more (Figueroa et al., 2015).
Highly myopic patients with MTM who experience a progressive
loss of BCVA in the context of an anatomical worsening on OCT seem to
be the most suitable candidates for an interventional approach. A range
of surgical techniques are available, as we describe in the next section.
6.3.3.2. Surgical techniques. Retinal surgery in highly myopic patients
is among the most difficult and challenging types of ophthalmological
surgery, even in expert hands. Not surprisingly, this type of surgery
carries a risk of iatrogenic complications. The main aim of surgery in
MTM is to reduce traction forces at the macula while avoiding inflicting
further damage to the retina in the process. To achieve this relaxation of
the macula, surgery can be performed ab interno using vitrectomy, with
or without the aid of an external modification of the scleral curvature at
the fovea, thus bringing the two structures closer together.
Pars plana vitrectomy (23-gauge) is a proven approach to improving
macular anatomy (Fig 16). However, the role of ILM peeling is not
clear. While ILM peeling reportedly reduces postoperative cellular
proliferation and ERM formation, it presents a higher risk of iatrogenic
lesions such as full-thickness MH while achieving a similar rate of
anatomic resolution (Qi et al., 2016). Supporters of ILM peeling believe
it is the most efficient way to completely remove all cortical vitreous
remnants from the retinal surface and that an ILM-free retina is more
elastic and thus more amenable to reattachment (Gaucher et al., 2007;
Bando et al., 2005). However, findings from a recent meta-analysis of
239 eyes treated with vitrectomy with or without ILM peeling showed
that although ILM peeling appears to yield better anatomic results (a
statistically significant odds ratio of 2.15), no statistically-significant
differences were achieved with regard to gains in BCVA or fewer
complications (Meng et al., 2017). For this reason, some groups have
proposed foveal-sparing modified peeling techniques, which leave part
of the ILM (between 300 and 2000 μm) in the centre of the macula, thus
protecting Müller cells and theoretically reducing the risk of MH de-
velopment, while also obtaining better visual and anatomic outcomes
(Fig 17); however, these findings are based on studies with relatively
small sample sizes (Shimada et al., 2012; Ho et al., 2014; Ho et al.,
2012).
Published reports indicate that the use of gas tamponade after vi-
trectomy results in more rapid anatomic improvements but with the
trade-off of higher complication rates and without any significant dif-
ferences (Meng et al., 2017; Uchida et al., 2014; Figueroa et al., 2015).
Scleral indentation, also known as macular buckling, was first de-
scribed by Schepens in 1957 (Schepens et al., 1957). This technique can
be used separately or in combination with pars plana vitrectomy to
further reduce tractional forces in MTM. However, it is a difficult
procedure with a long learning curve. The procedure consists of placing
an external device (which can be made of a range of different materials,
including donor sclera, silicone with and without stainless steel wires,
gore-tex, or long-lasting hyaluronic acid) to flatten the posterior sta-
phyloma to facilitate foveal attachment. This technique yields anatomic
success rates ranging from 25% to 100%, and, in most cases, no further
procedures are required (Alkabes and Mateo, 2018). The most com-
monly reported complications are RPE alterations, choroidal effusion,
buckle removal or malpositioning, and scleral perforations (Alkabes
and Mateo, 2018).
7. Myopic macular hole
7.1. Macular hole: overview
The development of a MH—a relatively common complication in
high myopia—is associated with significant visual impairment (Ikuno,
2017). Anteroposterior and tangential traction exerted by the vitreous
over the macula is closely related to the development of MH in myopic
eyes, similar to what occurs in emmetropic eyes. However, in the pre-
sence of a posterior staphyloma, which promotes retinal layer splitting,
myopic MH is commonly associated with foveoschisis, an important
difference compared to emmetropic MH. Overall, the presence of con-
comitant foveoschisis indicates a worse anatomic and functional prog-
nosis, which may even lead to retinal detachment (Ikuno and Tano,
2006). Increased axial length in conjunction with posterior staphyloma
are key factors for the development of myopic MH, which differentiates
it from non-myopic MH.
Lamellar or non-full-thickness MH is a common finding on OCT in
asymptomatic myopic patients. However, these cases can usually be
Fig. 16. Horizontal (a, b) and vertical (c, d) optical coherence tomography b-scans of a highly myopic patient before and after pars plana vitrectomy treatment with
posterior hyaloid and epiretinal membrane dissection and inner limiting membrane peeling for myopic traction maculopathy.
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managed by observation alone. Surgical intervention is necessary only
in the presence of a clear vitreous traction or visual decrease attribu-
table to the lamellar MH. Recently it has been reported that epiretinal
proliferation associated with lamellar myopic MH tend to be more
widespread and adherent to the posterior hyaloid than in non-myopic
eyes (Lai and Yang, 2017).
7.1.1. Macular hole: treatment
The goal of surgical repair is total closure of the MH to preserve or
improve BCVA. The gold standard treatment is posterior vitrectomy,
posterior hyaloid dissection, and ILM peeling (Fig. 18 and 19). Posterior
vitrectomy can be performed with 23-gauge or smaller instruments.
Importantly, the entire vitreous should be removed from the macular
surface. Vitreoschisis is common in myopic eyes and failure to identify
and remove this poses a risk to successful MH closure. Triamcinolone
can be used as an adjuvant to detect vitreoschisis and to induce a
complete posterior vitreous detachment. Likewise, trypan blue and
brilliant blue are helpful for ILM and ERM peeling. Current re-
commendations favour the use of blue dyes rather than indocyanine
green to stain the ILM due to potential retinal toxicity. ILM peeling in a
highly myopic eye is a challenging surgical manoeuvre due to several
factors: 1) greater length of the eye, 2) retinal thinning, 3) poor
staining, 4) difficult identification of the exact location of the MH.
Most surgeons perform a complete ILM peeling over the entire
macula in an attempt to reach the main vascular arcades. Nevertheless,
several alternative techniques have been proposed, particularly in MH
with foveoschisis, to achieve a successful closure (Ikuno, 2014). Some
authors perform an incomplete peeling, leaving an ILM shield over the
macula to protect the fovea (Shimada et al., 2012). This approach is
especially recommended in myopic MH with concomitant foveoschisis,
where retinal layer splitting weakens the fovea, making it more sus-
ceptible to damage.
The overall percentage of MH closure is lower in myopic eyes than
in emmetropic eyes. For this reason, an inverted ILM flap technique has
been proposed to enhance the probability of successful closure in
myopic MH (Kuriyama et al., 2013). This technique involves peeling the
ILM without breaking its attachment to the edge of the MH. Next, a
sheet of ILM is placed inside or over the MH bed to create a scaffold to
facilitate anatomical closure of the MH (Yamashiro et al., 2018). Im-
portantly, fluid-air exchange should be performed carefully to avoid
displacing the ILM flap.
Recently published studies report a clear advantage for the inverted
ILM flap technique versus standard ILM peeling—regardless of the
diameter—to achieve complete MH closure without any detrimental
visual results (Mete et al., 2017; Rizzo et al., 2017).
In most cases, gas tamponade with either sulphur hexafluoride (SF6)
or perfluoropropane (C3F8) is used. Facedown positioning is re-
commended for 3–7 days after surgery. However, silicone oil tampo-
nade can be used in selected patients in whom facedown positioning
cannot be guaranteed.
In cases of primary surgical failure or recurrence, two techniques
have been proposed: 1) placement of an ILM graft, obtained from a
peripheral area of the primary ILM peeling, over the MH, or 2) macular
buckling (Fig 20). Visual recovery after surgery depends on closure of
the MH and the status of the underlying photoreceptors and RPE.
However, the combination of increased axial length with a posterior
staphyloma is a risk factor for surgical failure (Ohsugi et al., 2018).
7.2. Macular hole retinal detachment: overview
Macular hole retinal detachment (MHRD) occurs mainly in patients
with high myopia who present a posterior staphyloma (Fig 21). How-
ever, it is not clear why some myopic patients with MH develop a
retinal detachment while others do not. A recently published retro-
spective study reviewed consecutive cases with axial length>28mm
treated with vitrectomy for MH or MHRD. That study showed that,
compared to eyes with MHRD, eyes with MH had significantly greater
choroidal and scleral thickness, a higher frequency of DSM, and a lower
staphyloma height (Ohsugi et al., 2018). Nevertheless, the cut-off point
for extreme myopia is generally considered to be 30mm in axial length
based on published results indicating that surgical outcomes are worse
in those eyes (Arias et al., 2015; Nadal et al., 2012). Therefore, MHRD is
mainly determined by the presence of an increased axial length with
concomitant staphyloma, similar to myopic MH.
7.2.1. Macular hole retinal detachment: treatment
MHRD is among the most difficult types of retinal detachment to
treat. Moreover, visual outcomes in these patients are often poor (Ortisi
et al., 2012). Before the advent of vitrectomy, MHRD patients were
treated with macular buckling and diathermy, or by cryo- or laser re-
tinopexy of the MH. However, anatomic outcomes were usually sub-
optimal due to excessive atrophy and fibrosis in the macular area.
Fig. 17. Progressive myopic traction maculopathy causing a foveal detachment (a) and a full-thickness macular hole (b). Macular anatomy was restored after pars
plana vitrectomy with epiretinal membrane and inner limiting membrane peeling (c, d).
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Vitrectomy consists of vitreous dissection and peeling of the ILM
and ERMs to reduce tangential and anteroposterior traction. It is these
tractions, in conjunction with posterior staphyloma, which lead to the
development of MHRD. Peeling is easier and safer when blue dyes are
used to stain the ILM and ERMs. Perfluorocarbon liquid can be used to
stabilize and flatten the macular surface before ILM peeling. Any sub-
retinal fluid displaced from the macula by the perfluorocarbon can be
removed through peripheral retinotomy. To avoid damaging the un-
derlying RPE, subretinal fluid aspiration through the MH should be
avoided. A recent study reported excellent results using the inverted
ILM flap technique to treat MHRD (Chen and Yang, 2016).
The choice of tamponade is controversial. While some authors
prefer gas, others recommend silicone oil to overcome reduced natural
adhesion due to staphyloma and chorioretinal atrophy (Chen et al.,
2006; Mancino et al., 2013; Nadal et al., 2012). Heavy silicone oil has
also been used, with favourable anatomical results (Avitabile et al.,
2011).
Various patterns of retinoschisis and MHRD evidence on FAF have
been described in high myopia (Sayanagi et al., 2007). On FAF, an axial
length>30mm and macular atrophy appear to be prognostic factors
for worse anatomic and visual outcomes (Arias et al., 2015).
Macular buckling is an alternative approach to treating recurrent or
difficult cases of MHRD because it facilitates MH closure by inserting a
ridge that pushes the whole macula forward. This could explain why
myopic eyes with MH and DSM are less susceptible to retinal detach-
ment; as occurs in eyes with implanted macular buckles, DSM reduces
the curvature of the staphyloma and may prevent retinal detachment
(Ohsugi et al., 2018). In this regard, some studies have reported better
results with macular buckling than with vitrectomy, even in primary
MHRD (Ando et al., 2007; Siam et al., 2012). Recent reports suggest
that combining macular buckling and vitrectomy with ILM peeling may
be a promising alternative in refractory cases (Ma et al., 2017).
Finally, posterior scleral contraction has been used to treat recurrent
or persistent MHRD in highly myopic eyes (Zheng et al., 2018). Scleral
expansion may contribute to the development of MHRD, which is why
contracting the posterior sclera could be an effective treatment to
Fig. 18. 81-year-old female who presented with 20/200 visual acuity (VA). Swept-source optical coherence tomography (SS-OCT) showed an outer foveoschisis with
a full-thickness macular hole (a). The patient underwent pars plana vitrectomy surgery + inner limiting membrane peeling + SF6 tamponade. Two months after
surgery her VA was 20/32, with resolution of the macular hole and improvement of the foveoschisis (b). Two years after surgery, SS-OCT imaging showed no signs of
foveoschisis and VA was 20/50 (c).
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reattach the retina and sclera and to relieve the outer traction exerted
on the retina.
8. Dome-shaped macula
DSM was first described by Gaucher et al. in highly myopic eyes
with visual impairment, metamorphopsia, and atrophic changes in the
RPE combined with focal points of limited leakage. On ultrasound and
OCT scans, there is a bulge in the macular retina, choroid, and RPE
within the posterior staphyloma; in a high percentage of cases, these
features are combined with a localized shallow retinal detachment at
the top of the macula (Gaucher et al., 2008) (Fig 22).
DSM was defined as a new type of staphyloma by Gaucher (Gaucher
et al., 2008). However, DSM was not included in Curtin’s initial clas-
sification (Curtin, 1977), and Imamura et al. stated that DSM was “the
result of a relative localized thickness variation of the sclera under the
macula in highly myopic patients”, which could not be classified into
any known type of staphyloma (Imamura et al., 2011). Previously, it
was suggested that all types of staphyloma might present single or
multiple septa, terraces and steps and therefore DSM might be con-
sidered one of these septa or steps, round shaped and located in the
macula (Fernandez-Vega Sanz et al., 2015).
Based on OCT findings, three different DSM morphologies have
been described according to the primary orientation. The most common
morphology is an oval-shaped, horizontally-oriented macula, which
accounts for approximately 60% of cases; the other two types are
rounded (20% of cases) and oval-shaped, vertically-oriented DSMs
(20%) (Caillaux et al., 2013).
Ohno-Matsui found that 18.5% of highly myopic eyes presented
DSM on MRI, even though most of the eyes had no posterior staphyloma
(Ohno-Matsui, 2014). Gaucher and colleagues described DSM as a
convex protrusion of the macula within a posterior staphyloma, gen-
erally in highly myopic eyes but also in eyes with low refractive error
(Gaucher et al., 2008).
Although the pathogenesis of DSM remains unclear, several authors
believe that it is related to a relative thickening of the sclera compared
to the surrounding areas (Fernandez-Vega Sanz et al., 2015; Ohsugi
et al., 2013). It has also been suggested that the RPE might be me-
chanically damaged by the protrusion of the dome within the staphy-
loma, thus leading to the accumulation of subretinal fluid, which might
also occur at the border of the staphyloma. Chronic subfoveal fluid—-
whose presence is associated with decreased vision—is more common
when the macular bulge is highly elevated. Curtin had previously
suggested that the septa and steps were less ectatic than the rest of the
staphyloma (Curtin, 1977). Focal resistance to scleral deformation may
also play a role in DSM development. Focal defects in the macular
Bruch’s membrane may be associated with areas of focal relaxation of
the posterior sclera, which permits the sclera in these areas to bulge
inward, thus leading to the formation of DSM (Fajardo Sánchez et al.,
2017). These focal defects of Bruch’s membrane have also been asso-
ciated with DSM (Fang et al., 2017). Fang et al. suggest that a weakened
Bruch’s membrane cannot push the sclera outwards, and so the sclera
bulges inwards, inducing the DSM (Fang et al., 2017). Several authors
have suggested that other factors may be involved in DSM, including
localized thickening of the choroid (Gaucher et al., 2008), ocular hy-
potony, scleral folds secondary to the collapse of the posterior ocular
wall, tangential vitreoretinal traction (Mehdizadeh and Nowroozzadeh,
2008), and areas of increased and decreased scleral thickness under the
macula (Imamura et al., 2011). Other reports indicate that DSM can
occur independently of staphyloma and might even develop prior to
staphyloma (Ellabban et al., 2014), a hypothesis that is potentially
supported by the early emergence of asymptomatic DSM in children.
The pathogenesis of neurosensory retinal detachment in DSM and at
the edge of the staphyloma has been attributed to a mild thickening of
the submacular choroid, which may be associated with subretinal fluid
(Errera et al., 2014; Gaucher et al., 2008). However, other authors have
Fig. 19. 68-year-old female patient showing a macular foveoschisis with foveal
detachment and a visual acuity (VA) of 20/100 (a,b). Two weeks later, the
patient’s condition worsened, with the development of a full-thickness macular
hole (MH) and a decrease in VA to 20/400 (c). Three months after pars plana
vitrectomy + inner limiting membrane peeling + silicone oil tamponade,
optical coherence tomography demonstrated complete resolution of the MH
and an improvement in VA to 20/40 (d).
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not found any differences between highly myopic eyes with and
without DSM (Imamura et al., 2011). A mechanism similar to what
occurs in nanophthalmia may be responsible for the formation of sub-
foveal fluid and for the increased scleral thickness that affects choroidal
flow, thus inducing serous detachment. However, other authors (Ohsugi
et al., 2013) have found no differences in choroidal thickness in eyes
with or without DSM-associated subfoveal fluid. Other reports suggest
the possible involvement of compressive changes in the choriocapillaris
as well as secondary RPE changes (Byeon and Chu, 2011). DSM may
represent an adaptive mechanism to scleral expansion in highly myopic
eyes (Viola et al., 2015).
Retinal serous detachment, typically associated with localized RPE
atrophy, may spontaneously appear and disappear in eyes with DSM. In
this regard, Soudier et al. evaluated a small series of patients, finding
that eyes without RPE atrophy did not present serous detachment
during follow-up (Soudier et al., 2016).
Several studies have described a marked thinning of the choroid at
the border of the staphyloma associated with retinal detachment and
mCNV (Ellabban et al., 2014; Maruko et al., 2011; Yamagishi et al.,
2012). Nevertheless, other authors have reported areas of choroidal
thinning and thickening, respectively, in the lower and upper borders of
the staphyloma, which might be related to the presence of subretinal
fluid (Fernandez-Vega Sanz et al., 2015).
On FA and ICGA, multiple pinpoint focal areas of hyperfluorescence
are often observed in the macular area due to RPE atrophy, without
vascular hyperpermeability, a finding that is occasionally associated
with minimal leakage.
A bulge height> 400 μm has been associated with decreased BCVA,
subfoveal serous detachment, and greater RPE atrophy (Fajardo
Sánchez et al., 2017). In eyes with DSM, BCVA usually remains stable
over time, even though the bulge height tends to increase. Subretinal
fluid may increase or disappear spontaneously, and RPE atrophy seems
to correlate with bulge height and fluid duration (Soudier et al., 2016).
It is likely that the DSM and subretinal fluid develop at early ages but
the RPE only becomes atrophic several years later, a hypothesis that is
supported by recent reports of DSM in children (Ellabban et al., 2014)
(Fig 23). This finding of DSM in children suggests that the presence of
DSM and subretinal fluid only become apparent when the RPE has
become atrophic and BCVA has started to decrease—thus prompting a
visit to the optometrist or ophthalmologist—and thus late in the de-
velopment of the condition.
DSM-associated subretinal fluid usually remains stable over time
while the RPE atrophies over time, leading to decreased visual function.
Complications include mCNV, ERM, lamellar and full-thickness MH,
and foveal and extrafoveal retinoschisis (Liang et al., 2015). However,
these complications can be successfully managed by intravitreal anti-
VEGF or surgery (Soudier et al., 2016).
8.1. Management
Presently, there is a lack of effective treatments to manage DSM-
associated subretinal fluid and fluid at the border of the staphyloma.
However, spontaneous resolution of subfoveal fluid in DSM has been
reported (Tamura et al., 2014). This possible spontaneous resolution
may mask the results of the treatments used in other series (laser
photocoagulation, verteporfin PDT, and intravitreal injection of anti-
angiogenic drugs, and steroids). Fernandez-Vega et al. retrospectively
evaluated patients treated with intravitreal bevacizumab and/or PDT,
finding that neither treatment (whether administered alone or in
combination) significantly improved BCVA or the quantity of subretinal
fluid; however, there were no treatment-related adverse effects
Fig. 20. Macular buckling can be used separately or in combination with pars plana vitrectomy to further reduce tractional forces in myopic traction maculopathy. It
is seen on optical coherence tomography images as a hyporeflective mass that indents the posterior pole of the eye under the fovea.
Fig. 21. The progressive nature myopic traction maculopathy may induce the
development of a full-thickness macular hole (MH) in severe cases, which can
lead to retinal detachment in patients with persistent traction over the margins
of the MH.
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(Fernandez-Vega Sanz et al., 2015). Several small studies involving
patients treated by bevacizumab and PDT have reported similar fin-
dings—that is, no changes in BCVA, OCT findings, or symptoms after
treatment (Chinskey and Johnson, 2013; Donati et al., 2013; Milani
et al., 2010). More recent studies in patients with DSM-associated
subretinal fluid treated by spironolactone have reported partial or
complete resolution of the subretinal fluid with no changes in BCVA
(Dirani et al., 2014; Fernández-Vega Sanz et al., 2016; Rocha Cabrera
et al., 2017).
In our experience, the DSM-associated decline in BCVA occurs very
slowly, usually appearing only several years after disease onset, an
observation that is consistent with previous reports (Alakeely and
Alrashaed, 2016; Soudier et al., 2016). Current therapies, such as
threshold laser photocoagulation and PDT to the hyperfluorescent
spots, may further damage the RPE, thus contributing to accelerated
BCVA loss.
A recent study in 2 eyes of patients with DSM-related serous retinal
detachment reported promising results at 12 months of follow-up after
subthreshold laser treatment(Battaglia Parodi et al., 2017). Patients in
that study underwent a single session of subthreshold laser treatment to
cover the hyperfluorescent area evidenced on ICGA. Importantly, out-
comes included a significant gain in BCVA, a decrease in central foveal
thickness and subretinal fluid, and complete resolution in one case.
After treatment, the hyperfluorescence was no longer evident on FA and
ICGA.
9. Current challenges and future directions
Many unanswered questions remain about both high and pathologic
myopia. For example, the mechanism driving the development of pos-
terior staphyloma remains unclear. Axial length cannot be the only
cause given the existence of reports of patients with staphyloma
without high myopia (Wang et al., 2016) in which changes in collagen
fibres surrounding the optic nerve have been implicated (McBrien and
Gentle, 2003). The emergence of newer imaging modalities, such as
polarization-sensitive OCT (Yamanari et al., 2008) and deep-penetrance
SS-OCT will allow us to better evaluate the sclera and broaden our
understanding of the sclera in the posterior pole of highly myopic eyes.
There are many open questions. Are high and pathologic myopia the
same disease at different stages? Is it a matter of gene penetrance? Are
they two independent diseases? Is the presence of posterior staphyloma
sufficient to define high myopia? Given that pathologic myopia is a
progressive disease, what is the first sign? What is the best surgical
technique to assess MTM, given the difficulty and potential complica-
tions of surgery?
Posterior staphyloma plays a key role in myopic maculopathy by
inducing anatomic alterations that stretch the tissues of the posterior
pole, leading to traction, atrophy, and CNV. Multimodal imaging is the
best approach to achieving an accurate diagnosis in those patients. The
value of multimodal imaging can be seen in early stage MTM, which
can only be detected by OCT. In addition, the “low” activity of mCNV
makes a multimodal approach essential. FA is more sensitive than SD-
OCT in detecting mCNV (82% vs. 48.6%) (Leveziel et al., 2013), but
combing these two modalities increases the sensitivity to 97% (García-
Fig. 22. Horizontally-oriented dome-shaped maculopathy with subfoveal fluid. (a) Colour fundus photography shows a juxtapapillary area of choroidal pallor. (b–c)
Vertical and horizontal B-scan imaging show posterior pole staphyloma. (d) Spectral-Domain optical coherence tomography shows the presence of subfoveal fluid
with oblique orientation of the posterior pole sclera, which is associated with (e) defective subfoveal autofluorescence corresponding to the area affected by subfoveal
fluid.
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Layana et al., 2006). OCTA is another promising imaging technique in
retinal vascular diseases, including mCNV. However, this technology
requires further refinement to improve image quality, to minimize ar-
tefacts, and to improve field-of-view and segmentation in high myopic
eyes with thin choroids, thin sclera, and posterior staphyloma. Aside
from imaging studies, the symptoms of myopic patients must also be
considered when signs of activity are not evident on imaging scans.
Myopic CNV often turns into scar tissue (stage 2 disease on OCT
studies). Atrophic changes tend to develop around this scar tissue, thus
leading to stage 3 disease on OCT. Similarly, chorioretinal atrophy will
develop around this lesion, leading to atrophic myopic maculopathy
over time. Chorioretinal atrophy around the regressed neovascular le-
sion, probably secondary to RPE damage, is a key factor in the pro-
gressive decrease in BCVA over time (Neelam et al., 2012). There are
reports that state that this atrophy is, in fact, caused by enlarged defects
of the Bruch’s membrane rather than simply chorioretinal atrophy. For
this reason, if fibrosis can be prevented, then BCVA loss due to CNV-
related atrophy could be reduced in the medium to long-term. Cur-
rently, new treatments to reduce fibrosis induction in neovascular AMD
are being evaluated in clinical studies. Future therapies should focus on
preventing subretinal fibrosis, a characteristic feature of the scarring
stage in mCNV, where atrophic areas eventually develop over time,
resulting in vision loss. One possible treatment target is the inhibition of
platelet-derived growth factor (PDGF), which is involved in pericyte
loss. This target is interesting because pericytes are a major source of
myofibroblasts, which are critical in the formation of tissue fibrosis. A
clinical trial evaluated Fovista, an anti-PDGF aptamer (Ophthotech,
New York, NY), administered by intravitreal injection in combination
with anti-VEGF drugs for the treatment of neovascular AMD (Jaffe
et al., 2016). Fovista (or similar molecules) could be applied to mCNV
to reduce or prevent scarring, thus avoiding the chorioretinal atrophy
that develops around the scar tissue.
The use of modified ILM peeling techniques will improve outcomes
in MTM. A recent meta-analysis of patients treated with vitrectomy
with or without ILM peeling concluded that although ILM peeling may
lead to better anatomic outcomes, the use of ILM peeling did not result
in a statistically-significant improvement in BCVA, nor did it lead to
fewer complications (Meng et al., 2017). Modified peeling techniques
that involve foveal sparing of the ILM in the centre of the macula have
been proposed to protect Müller cells, thus reducing the risk of MH
while also obtaining better outcomes (Ho et al., 2014, 2012; Shimada
et al., 2012). Compared to ILM peeling, the inverted ILM flap technique
can be used to treat myopic MH regardless of the diameter (Mete et al.,
2017; Rizzo et al., 2017). When axial elongation and posterior sta-
phyloma are both present, there is an increased risk of surgical failure
in MH closure (Ohsugi et al., 2018); the definition of extreme myopia
was established as axial length> 30mm, as studies have shown that
surgical results are worse in these eyes (Arias et al., 2015; Nadal et al.,
2012).
Macular buckling (Schepens et al., 1957), performed alone or in
combination with pars plana vitrectomy, facilitates foveal attachment
(success rates range from 25% to 100%) but may induce some com-
plications (Alkabes and Mateo, 2018). Combining macular buckling,
vitrectomy, and ILM peeling has shown promising results in refractory
cases (Ma et al., 2017).
Two mechanisms contribute to scleral deformation: elasticity and
creep (Lewis et al., 2014). Elasticity refers to a reversible, instantaneous
deformation associated with a change in an applied stress. By contrast,
Fig. 23. Obliquely-oriented dome-shaped maculopathy with subfoveal fluid in an asymptomatic 6-year-old boy with visual acuity of 20/25. (a) Colour fundus
photography shows an oblique staphyloma between the fovea and the optic disk. (b–c) Vertical and horizontal B-scan imaging show posterior pole staphyloma. (d)
Spectral-Domain optical coherence tomography reveals an extremely obliquely-oriented posterior pole without subretinal fluid. (e) Defective subfoveal auto-
fluorescence corresponding to the area affected by subfoveal fluid.
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creep refers to a time-dependent deformation associated with a constant
applied stress. Intraocular pressure can provide a constant applied
stress to scleral collagen fibres. Scleral collagen exhibits a relatively
annular organization around the optic nerve and macular area, which
are the areas most susceptible to expansion under the constant force
associated with normal intraocular pressure (McBrien and Gentle,
2003). Myopic eyes exhibit reduced scleral rigidity compared to em-
metropic and hyperopic eyes (Sergienko and Shargorogska, 2012). In
preclinical models, inhibition of collagen crosslinking augments the
degree of induced myopia (Mcbrien and Norton, 1994). A number of
different approaches have been used to induce scleral collagen cross-
linking with the goal of increasing scleral rigidity to reduce expansion
of the vitreous cavity (Babar et al., 2015; Liu and Wang, 2013; Stewart
et al., 2009; Trier et al., 1999; Wollensak et al., 2003; Wollensak and
Iomdina, 2009; Wong et al., 2012). Depending on the treatment para-
meters, some of these methods have been associated with retinal toxi-
city (Zhang et al., 2013) or discoloration of the sclera (Liu and Wang,
2013). Non-selective crosslinking may damage collagen components of
blood vessels supplying the choroid and outer retina (Elsheikh and
Phillips, 2013). Given that scleral thinning in high myopia is most
pronounced in the posterior pole and peripapillary retina (Curtin et al.,
1979), treatment should probably be directed at the sclera overlying the
area centralis; however, one preclinical study suggested that equatorial
treatment might be effective (Dotan et al., 2014) Scleral myofibroblasts,
which may also influence scleral mechanical properties (Phillips and
McBrien, 2004), might also be damaged with this approach. Trans-
scleral solute diffusion and hydraulic conductivity are altered by
crosslinking (Stewart et al., 2009), and it is not clear what effect this
change might have on ocular health.
Cell-based therapies might be useful to stabilize scleral tissue bio-
mechanics (Janowski et al., 2015). Scleral fibroblasts seem to play a
critical role in modulating scleral biomechanical properties (McBrien,
2013; McBrien and Gentle, 2003). Scleral fibroblast transplants might
provide a means to stabilize scleral biomechanics without the attendant
risks of altered scleral diffusion properties, retinal or blood vessel da-
mage; moreover, such a procedure would be quite simple, similar to
retrobulbar fibroblast injection. Shinohara et al. used this technique
experimentally, successfully reinforcing the sclera of rats using newly
synthesized collagen fibrils, thereby reducing axial elongation and the
risk of myopia (Shinohara et al., 2018).
At present it is not known whether there are genetic differences
between high and pathologic myopia. Some authors suggest the ex-
istence of a pathological difference between the high myopia induction
phase and the development of myopic maculopathy that may be
mediated, at least in part, by genetics. Treatments targeting CCDC102B
may thus prevent the development of myopic maculopathy and blind-
ness, even after the patient has developed high myopia (Hosoda et al.,
2018).
Determination of the genetic basis of myopic maculopathy could
lead to the development of new strategies to prevent myopia-induced
low vision and blindness. It is important to clarify whether myopic
maculopathy is an inevitable consequence of high myopia or if these are
independent processes with their own genetic and environmental in-
fluences. New studies, with larger sample sizes from a range of different
populations and ethnicities, would help us to better understand myopic
maculopathy and to better estimate possible responses to novel thera-
pies. New experimental models of posterior staphyloma and chorior-
etinal atrophy may also be a promising approach to broadening our
understanding (Cases et al., 2015).
In the introduction to the present document, we noted the clear
need for a simple, universally-accepted classification system for myopic
maculopathy that could be used in future studies to ensure compar-
ability. Although the current classification system for atrophic myopic
maculopathy (Ohno-Matsui et al., 2015) is well-suited to identify the
various stages of atrophy, it is insufficient, in our opinion, because it
fails to account for the tractional component and also considers mCNV
as a “plus sign” only.
Several simple, practical classification systems are currently used to
classify many eye diseases. For example, the pterygium classification
system shown below (Table 3) is quite simple, and the most important
characteristics of the disease can be easily coded using only three letters
(Pastor-Vivas et al., 2011). In this system, a hypertrophic pterygium
invading 3.5mm of the cornea and covering 6.1 mm of limbus would be
a T3C2L3. Other fields, most notably oncology, also use relatively
simple classification systems, with the TNM cancer staging system
being one of the best examples (Gospodarowicz et al., 2004).
We believe that a similar classification system would be useful in
myopic maculopathy. Such a system would integrate some of the cur-
rently existing classification systems (Ohno-Matsui et al., 2015), but
would include tractional and neovascular components, which play a
highly relevant clinical role.
The main classification systems currently available the following:
• Foveoschisis: extension. (Shimada et al., 2013) (Table 2).
• Foveoschisis: layers involved (Fujimoto et al., 2010; Ceklic et al.,
2017) (Table 4)
• Atrophy (Ohno-Matsui et al., 2015) (Table 5)
We propose a new system based on three key factors: atrophy (A),
traction (T), and neovascularization (N), which we call the ATN clas-
sification system. This system would include the three most important
myopic alterations, thus allowing classification in a simple, systematic
manner that is both easy to apply and understand. This proposed
classification system does not make any changes to the current atrophy
classification, but it does include new proposals for the classification of
the tractional and neovascular components, as follows (Table 6).
For example: a patient with patchy atrophy, foveal tractional
Table 3
TCL Pterygium classification.
T (body) C (central invasion) L (limal invasion)
1 Atrophic 0–2mm 0–4mm
2 Moderate 2–4mm 4–6mm
3 Hypertrophic >4mm >6mm
Table 4
Myopic foveoschisis classification according to layer involvement (Fujimoto et al., 2010; Ceklic et al., 2017).
Inner Outer Inner + Outer
Involved layers IPL + GCL + RNFL OPL + ONL IPL + GCL + RNFL + OPL + ONL
IPL: Inner plexiform layer; GCL: Ganglion cell layer; RNFL: Retinal fiber layer; OPL: Outer plexiform layer; IPL: Inner plexiform layer.
Table 5
Myopic maculopathy atrophy-based classification (Ohno-Matsui et al., 2015).
Atrophy degree “Plus” signs
0 no myopic retinal lesions Lacquer cracks
1 tessellated fundus only Fuch’s spot
2 diffuse chorioretinal atrophy Myopic CNV
3 patchy chorioretinal atrophy
4 macular atrophy
CNV: Choroidal neovascularization.
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detachment without MH, and a CNV scar would be classified as
A3T3N2s. Precisely defining the stage of myopic maculopathy would
allow for a better follow-up and would help to unify clinical findings for
research purposes (Fig. 24 and 25). Changes of a patient’s ATN classi-
fication with time would give us information about the course and
evolution of the disease and its natural history. Currently, our group is
carrying out a study to verify the value of this proposed classification
system and to determine the inter-observer correlation and potential
applications.
Table 6
New proposed classification system for myopic maculopathy, which considers atrophic (A), tractional (T) and neovascular (N) components.
Atrophic component (A) Tractional component (T) Neovascular component (N)
A0: no myopic retinal lesions T0: No macular schisis N0: No Myopic CNV
A1: tessellated fundus only T1: Inner or outer foveoschisis N1: Macular lacquer cracks
A2: diffuse chorioretinal atrophy T2: Inner + outer foveoschisis N2a: Active CNV
A3: patchy chorioretinal atrophy T3: Foveal detachment N2s: Scar / Fuch’s spot
A4: complete macular atrophy T4: Full-thickness MH
T5: MH + Retinal detachment
CNV: Choroidal neovascularization; MH: Macular hole.
Fig. 24. Examples of the proposed new ATN classification system for myopic maculopathy. a) A highly myopic patient with a lacquer crack on fundus photography
and inner and outer retinoschisis on optical coherence tomography (OCT); ATN classification: A1T2N1. b) Patient with diffuse atrophy and a subtle foveal hae-
morrhage on fundus photography accompanied by an active choroidal neovascularization (CNV) lesion on OCT would be classified as A2T0N2a. c) Highly myopic
patient with a tessellated fundus and no lesions or tractions identified on OCT would be ATN stage A1T0N0.
Fig. 25. Example of the follow-up and evolution of a highly myopic patient using the ATN classification system a) Tessellated fundus, active CNV lesion with
subretinal and intreretinal fluid with no foveoschisis (A1T0N2a). b) Eight years later the patient complaint of visual acuity loss and showed patchy chorioretinal
atrophy with a Fuch’s spot and an inner foveoschisis (A3T1N2s). c) The patient underwent pars plana vitrectomy with inner limiting membrane peeling with a
complete resolution of his foveoschisis, turning into stage (A3T0N2s).
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